AU2022206708A1

AU2022206708A1 - Methods For Increasing Powdery Mildew Resistance In Cannabis

Info

Publication number: AU2022206708A1
Application number: AU2022206708A
Authority: AU
Inventors: Shira COREM; Ido Margalit; Tal SHERMAN
Original assignee: Betterseeds Ltd
Current assignee: Betterseeds Ltd
Priority date: 2021-08-19
Filing date: 2022-07-18
Publication date: 2023-03-09
Also published as: IL295293A; CA3166209A1

Abstract

The present invention discloses a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM). The aforementioned modified Cannabis plant comprises a mutated Cannabis mlol (Csmlol) allele comprising a genomic modification selected from an indel of 14 bp at position corresponding to position 12 of SEQ ID NO: 882, or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof. The present invention further discloses methods for production of the modified Cannabis plant using genome modification.

Description

METHODS FOR INCREASING POWDERY MILDEW RESISTANCE IN CANNABIS FIELD OF THE INVENTION

The present disclosure relates to conferring pathogen resistance in Cannabis plants. More particularly, the current invention pertains to producing fungal resistant Cannabis plants by controlling genes conferring susceptibility to such pathogens.

BACKGROUND OF THE INVENTION

Cannabis is one of the oldest domesticated plants with evidence of being used by a vast array of ancient cultures. It is thought to have originated from central Asia from which it was spread by humans to China, Europe, the Middle East and the Americas. Thus, Cannabis has been bred by many different cultures for various uses such as food, fiber and medicine since the dawn of agricultural societies. In the last few decades, Cannabis breeding has stopped as it became illegal and non-economic to do so. With the recent legislation converting Cannabis back to legality, there is a growing need for the implementation of new and advanced breeding techniques in future Cannabis breeding programs. This will allow speeding up the long process of classical breeding and accelerate reaching new and genetically improved Cannabis varieties for fiber, food and medicine products. Developing and implementing molecular biology tools to support the breeders, will allow creating new fungal resistant traits and tracking the movement of such desired traits across breeders germplasm.

Currently, breeding of Cannabis plants is mostly done by small Cannabis growers. There is very limited if any molecular tools supporting or leading the breeding process. Traditional Cannabis breeding is done by mixing breeding material with hope to find the desired traits and phenotypes by random crosses. These methods have allowed the construction of the leading Cannabis varieties on the market today. As the cultivation of Cannabis intensifies in protected structures such as greenhouses and closed growth chambers, such an environment encourages the prevalence of certain diseases, with the lead cause being fungi.

Powdery mildew is a fungal disease that affects a wide range of plants. Powdery mildew diseases are caused by many different species of fungi in the order Erysiphales, with Podosphaeraxanthii being the most commonly reported cause. Powdery mildew is one of the easier plant diseases to identify, as its symptoms are quite distinctive. Infected plants display white powdery spots on the leaves and stems. The lower leaves are the most affected, but the mildew can appear on any above ground part of the plant. As the disease progresses, the spots get larger and denser as large numbers of asexual spores are formed, and the mildew may spread up and reduce the length of the plant.

Powdery mildew grows well in environments with high humidity and moderate temperatures. Greenhouses provide an ideal moist, temperate environment for the spread of the disease. This causes harm to agricultural and horticultural practices where powdery mildew may thrive in a greenhouse setting. In an agricultural or horticultural setting, the pathogen can be controlled using chemical methods, bio organic methods, and genetic resistance. It is important to be aware of powdery mildew and its management as the resulting disease can significantly reduce important crop yields.

MLO proteins function as negative regulators of plant defense to powdery mildew disease. Loss of-function mlo alleles in barley, Arabidopsis and tomato have been reported to lead to broad spectrum and durable resistance to the fungal pathogen causing powdery mildew.

US6211433 and US6576814 describe modulating the expression of Mlo genes in Maize by producing transgenic plants comprising mutation-induced recessive alleles of maize Mlo. However, such methods require genetically modifying the plant genome, particularly transforming plants with external foreign genes that enhance disease resistance.

US2018208939 discloses the generation of mutant wheat lines with mutations inactivating MLO alleles which confer heritable resistance to powdery mildew fungus.

Cannabis cultivation has always suffered from fungal diseases due to high humidity growing conditions in growth rooms or greenhouses.

In view of the above there is a heightened immediate need for the development of Cannabis plants that carry genetic resistance to fungal diseases, thereby reducing or eliminating the need for fungicide use in the cultivation of Cannabis. In addition, there is a need for non-GMO, advanced breeding programs of Cannabis for food, medicine and fiber (Hemp) production.

SUMMARY OF THE INVENTION

It is therefore one object of the present invention to disclose a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein the modified plant comprises a mutated Cannabis mlol (Csmlol) allele, the mutated allele comprising a genomic modification selected from an indel of 14 bp at position corresponding to position 12 of SEQ ID NO: 882, or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined above, wherein the indel comprises a sequence as set forth in SEQ ID NO:883 or a fraction thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of the mutated Csmlol allele, or a complementary sequence thereof, or any combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of the mutated Csmlol allele.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the mutated Csmlol allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele having a nucleic acid sequence as set forth in SEQ ID NO:882 and/or having a nucleic acid sequence as set forth in SEQ ID NO:1 or a functional variant thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the functional variant has at least 80% sequence identity to the corresponding CsMLO1 nucleotide sequence.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the mutated allele comprising a deletion of 14 bp at position 389 of SEQ ID NO: 1, or a nucleic acid insertion at position 482-483 of SEQ ID NO: 1, or a combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the mutated Csmlol allele is generated using genome editing.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the plant has decreased expression levels of Mlo Iprotein, relative to a Cannabis plant lacking the mutated Csmlol allele.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the mutated Csmlol allele is generated using mutagenesis, small interfering RNA (siRNA), microRNA (miRNA), artificial miRNA (amiRNA), DNA introgression, endonucleases or any combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the endonuclease is selected from the group consisting of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) gene (CRISPR/Cas), Transcription activator-like effector nuclease (TALEN), Zinc Finger Nuclease (ZFN), meganuclease or any combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the Cas gene is selected from the group consisting of Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, CasIO, CastlOd, Cas12, Cas13, Cas14, CasX, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpfl, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Cszl, Csx15, Csfl, Csf2, Csf3, Csf4, and Cu1966, bacteriophages Cas such as Cas(D (Cas-phi) and any combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the plant comprises a DNA construct, the DNA construct comprising a promoter operably linked to a nucleotide sequence encoding a plant optimized Cas9 endonuclease, wherein the plant optimized Cas9 endonuclease is capable of binding to and creating a double strand break in a genomic target sequence of the plant genome.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the DNA construct further comprises gRNA targeted to at least one CsMLO1 allele.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the gRNA has a nucleic acid sequence corresponding to a sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, or any combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the genome modification is a silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation or any combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the genome modification is an insertion, deletion, indel or substitution.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the genome modification is an induced mutation in the coding region of the allele, a mutation in the regulatory region of the allele, a mutation in a gene downstream in the MLO pathogen response pathway and/or an epigenetic factor.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the genome modification is generated via introduction (a) Cas DNA and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 and any combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the gRNA sequence comprises a 3' Protospacer Adjacent Motif (PAM) selected from the group consisting of NGG (SpCas), NNNNGATT (NmeCas9), NNAGAAW (StCas9), NAAAAC (TdCas9), NNGRRT (SaCas9) and TBN (Cas-phi).

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the PM is selected from the group consisting of Golovinomyces cichoracearum,Golovinomyces ambrosiae and a mixture thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the Cannabis plant is selected from the group of species that includes, but is not limited to, Cannabis sativa (C. sativa), C. indica, C. ruderalis and any hybrid or cultivated variety of the genus Cannabis.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the Cannabis plant does not comprise a transgene.

It is another object of the present invention to disclose a modified Cannabis plant, progeny plant, plant part or plant cell as defined in any of the above.

It is another object of the present invention to disclose a plant part, plant cell or plant seed of a modified plant as defined in any of the above.

It is another object of the present invention to disclose a tissue culture of regenerable cells, protoplasts or callus obtained from the modified Cannabis plant as defined in any of the above.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the plant genotype is obtainable by deposit under accession number with NCIMB Aberdeen AB21 9YA, Scotland, UK.

It is another object of the present invention to disclose a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein the modified plant comprises a targeted genome modification conferring reduced expression of a Cannabis MLO1 (CsMLO1) gene as compared to a Cannabis plant lacking the targeted genome modification, the targeted genome modification generates a mutated Cannabis mlol (Csmlol) allele comprising a deletion of a nucleic acid sequence as set forth in SEQ ID NO:883 or a fraction thereof as compared to the wild type CsMLO1 allele comprising a sequence as set forth in SEQ ID NO:1, or a nucleic acid insertion at position 482-483 of SEQ ID NO:1, or a combination thereof.

It is another object of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein the mutated allele comprising a deletion of 14 bp at position 389 of SEQ

ID NO: 1, or a nucleic acid insertion at position 482-483 of SEQ ID NO: 1, or a combination thereof.

It is another object of the present invention to disclose a method for producing a modified Cannabis plant as defined in any of the above, the method comprises introducing using targeted genome modification, at least one genomic modification conferring reduced expression of at least one Cannabis MLO1 (CsMLO1) allele as compared to a Cannabis plant lacking the targeted genome modification, the genomic modification generates a mutated Cannabis mlol (Csmlol) allele comprising an indel of 14 bp at a position corresponding to position 12 of SEQ ID NO: 882 or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof.

It is another object of the present invention to disclose the method as defined above, comprises steps of introducing a loss of function mutation into the CsMLO1 allele using targeted genome modification.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the indel comprises a sequence as set forth in SEQ ID NO:883 or a fraction thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of the mutated Csmlol allele, or a complementary sequence thereof, or any combination thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of the mutated Csmlol allele.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the mutated Csmlol allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele having a nucleic acid sequence as set forth in SEQ ID NO:882 and/or having a nucleic acid sequence as set forth in SEQ ID NO:1 or a functional variant thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the functional variant has at least 80% sequence identity to the corresponding CsMLO1 nucleotide sequence.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the mutated allele comprising a deletion of 14 bp at position 389 of SEQ ID NO: 1, or a nucleic acid insertion at position 482-483 of SEQ ID NO: 1, or a combination thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the modified plant has decreased levels of at least one Mlo protein as compared to wild type Cannabis plant.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the genome modification is introduced using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) gene (CRISPR/Cas), Transcription activator-like effector nuclease (TALEN), Zinc Finger Nuclease (ZFN), meganuclease or any combination thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the Cas gene is selected from the group consisting of Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, CasIO, CastlOd, Cas12, Cas13, Cas14, CasX, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpfl, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Cszl, Csx15, Csfl, Csf2, Csf3, Csf4, and Cu1966, bacteriophages Cas such as Cas(D (Cas-phi) and any combination thereof.

It is another object of the present invention to disclose the method as defined in any of the above, comprising steps of introducing an expression vector comprising a promoter operably linked to a nucleotide sequence encoding a plant optimized Cas9 endonuclease and gRNA targeted to at least one CsMLO1 allele.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the gRNA nucleotide sequence targeting the CsMLO1 allele is selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof.

It is another object of the present invention to disclose the method as defined in any of the above, comprising steps of introducing and co-expressing in a Cannabis plant Cas9 and gRNA targeted to CsMLO1 gene and screening for induced targeted mutations conferring reduced expression of the CsMLO1 gene.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the genomic modification is in the coding region of the allele, a mutation in the regulatory region of the allele, a mutation in a gene downstream in the MLO pathogen response pathway or an epigenetic factor.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the genomic modification is selected from the group consisting of a silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation and any combination thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the genomic modification is an insertion, deletion, indel or substitution mutation.

It is another object of the present invention to disclose the method as defined in any of the above, further comprising steps of selecting a plant resistant to powdery mildew from plants comprising mutated Csmlol allele.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the selected plant is characterized by enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a CsMLO1 nucleic acid comprising a nucleic acid sequence as set forth in SEQ ID NO:882.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the genetic modification in the CsMLO1 is generated in planta via introduction of a construct comprising (a) Cas DNA and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, and any combination thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the gRNA nucleotide sequence comprises a 3' Protospacer Adjacent Motif (PAM) selected from the group consisting of NGG (SpCas), NNNNGATT (NmeCas9), NNAGAAW (StCas9), NAAAAC (TdCas9), NNGRRT (SaCas9) and TBN (Cas-phi).

It is another object of the present invention to disclose the method as defined in any of the above, further comprising steps of regenerating a plant carrying the genomic modification.

It is another object of the present invention to disclose the method as defined in any of the above, further comprising steps of screening the regenerated plants for a plant resistant to powdery mildew.

It is another object of the present invention to disclose the method as defined a method for conferring powdery mildew resistance to a Cannabis plant comprising producing a plant according to the method as defined in any of the above.

It is another object of the present invention to disclose a plant, plant part, plant cell, tissue culture or a seed obtained or obtainable by the method as defined in any of the above.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the powdery mildew is selected from the group of species consisting of Golovinomyces cichoracearum,Golovinomyces ambrosiae and a mixture thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the Cannabis plant is selected from the group of species that includes, but is not limited to, Cannabis sativa (C. sativa), C. indica, C. ruderalisand any hybrid or cultivated variety of the genus Cannabis.

It is another object of the present invention to disclose a method of determining the presence of a mutant Csmlol allele in a Cannabis plant comprising assaying the Cannabis plant for at least one of the presence of an indel comprising a nucleic acid sequence as set forth in SEQ ID NO:883, an insertion at position 104-105 of SEQ ID NO: 882, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of the mutated Csmlol allele, a complementary sequence thereof, or any combination thereof.

It is another object of the present invention to disclose a method for identifying a Cannabis plant with resistance to powdery mildew, the method comprises steps of: (a) screening the genome of the Cannabis plant for a mutated Csmlol allele, the mutated allele comprises a genomic modification selected from an indel of 14 bp at a position corresponding to position 12 of SEQ ID NO: 882 or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104 105 of SEQ ID NO: 882, or a combination thereof; (b) optionally, regenerating plants carrying the genetic modification; and (c) optionally, screening the regenerated plants for a plant resistant to powdery mildew.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the genomic modification is a loss of function mutation.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the indel comprises a sequence as set forth in SEQ ID NO:883 or a fraction and/or a complementary sequence thereof.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the method comprises steps of screening the Cannabis plant for the presence of a deletion in CsMLO1 gene comprising a nucleic acid sequence as set forth in SEQ ID NO:1, the deletion comprising a nucleotide sequence as set forth in SEQ ID NO:883.

It is another object of the present invention to disclose the method as defined in any of the above, wherein the modified Cannabis plant comprising a mutant Csmlol nucleic acid conferring enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 nucleic acid.

It is another object of the present invention to disclose a method for down regulation of Cannabis MLO1 (CsMLO1) gene, which comprises utilizing the nucleotide sequence as set forth in at least one of SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, and a combination thereof, for introducing a loss of function mutation into the CsMLO1 gene using targeted genome modification.

It is another object of the present invention to disclose an isolated amino acid sequence having at least 80% sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:882-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof.

It is another object of the present invention to disclose use of a nucleotide sequence as set forth in SEQ ID NO: 883-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 for generating, identifying and/or screening for a Cannabis plant comprising within its genome mutant Csmlo allele conferring resistance to PM.

It is another object of the present invention to disclose the use as defined in any of the above, wherein the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:883, SEQ ID NO:882 indicates that the Cannabis plant comprises a wild type CsMLO1 allele, and the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:884, SEQ ID NO:885 and SEQ ID NO:886 indicates that the Cannabis plant comprises a mutant Csmoll allele.

It is another object of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof for targeted genome modification of Cannabis MLO1 (CsMLO1) gene.

It is another object of the present invention to disclose a detection kit for determining the presence or absence of a mutant Csmlol allele in a Cannabis plant, comprising a nucleic acid fragment comprising a sequence selected from SEQ ID NO:882-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof.

It is another object of the present invention to disclose the detection kit as defined above, wherein the kit is useful for identifying a Cannabis plant with enhanced resistance to powdery mildew.

BRIEF DESCRIPTION OF THE FIGURES

Exemplary non-limited embodiments of the disclosed subject matter will be described, with reference to the following description of the embodiments, in conjunction with the figures. The figures are generally not shown to scale and any sizes are only meant to be exemplary and not necessarily limiting. Corresponding or like elements are optionally designated by the same numerals or letters.

Figs 1A-C is presenting a photographic illustration of an infected Cannabis plant leaf exhibiting PM symptoms of white powdery spots on the leaves (Fig. 1A), an enlarged view (X4) of fungal asexual spore-carrying bodies (conidia) of Golovinomyces cichoracearumon Cannabis leaf tissue (Fig. IB), and a microscopic imaging of Golovinomyces cichoracearumspores (Fig. IC);

Fig. 2A-B is schematically presenting WT plant cell penetrated by the fungal appressorium leading to haustorium establishment and infection by secondary hyphae (Fig. 2A), and mlo knockout plant cell into which the fungal spores are incapable of penetrating (Fig. 2B);

Fig. 3 is schematically presenting CRISPR/Cas9 mode of action as depicted by Xie, Kabin, and Yinong Yang. "RNA-guided genome editing in plants using a CRISPR-Cas system." Molecular plant 6.6 (2013): 1975-1983;

Fig. 4A-D is photographically presenting GUS staining after transient transformation of Cannabis axillary buds (Fig. 4A), leaves (Fig. 4B), calli (Fig. 4C), and cotyledons (Fig. 4D);

Fig. 5 is presenting regenerated Cannabis tissue;

Fig. 6 is photographically presenting PCR detection of Cas9 DNA in shoots of Cannabis plants transformed using biolistics;

Fig. 7A-B is illustrating in vitro cleavage activity of CRISPR/Cas9; a scheme of genomic area targeted for editing is shown in Fig. 7A, and a gel showing digestion of PCR amplicon containing the gRNA sequence by RNP complex containing Cas9 and gene specific gRNA is shown in Fig. 7B;

Fig. 8 is presenting a schematic illustration of a DNA plasmid containing a plant codon optimized Cas9 nuclease from Streptococcus pyogenes (pcoSpCas9) and sgRNA sequences used for transformation, as embodiments of the present invention;

Fig. 9 schematically presents genomic localization of sgRNAs used for targeting CsMLO1 first exon, as embodiments of the present invention;

Fig. 10 presents genomic nucleotide sequence of the first exon (exon 1) of wild type CsMLO1 targeted by three gRNA sequences;

Fig. 11 presents amino acid sequence of the first exon (exon 1) of wild type CsMLO1;

Fig. 12 photographically presents detection of CsMLO1 PCR products showing length variation as a result of Cas9- mediated genome editing;

Fig. 13 schematically presents genome edited CsMLO1 DNA fragments produced by the present invention; and

Fig. 14 schematically presents nucleic acid sequence comparison of WT CsMLO1 and genome edited Csmlol_dl4i1 fragments produced by the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which are shown by way of illustration specific embodiments in which the invention may be practiced. It is understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention. The present invention may be practiced according to the claims without some or all of these specific details. For the purpose of clarity, technical material that is known in the technical fields related to the invention has not been described in detail so that the present invention is not unnecessarily obscured.

The present invention provides a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein the plant comprises a targeted genome modification conferring reduced expression of at least one Cannabis MLO (CsMLO) allele as compared to a Cannabis plant lacking said targeted genome modification.

The present invention is aimed at showing that lack of mildew resistance loci 0 (MLO) genes in Cannabis is correlated with resistance to PM. It is herein disclosed that MLO deletions are likely to increase PM resistance in Cannabis. According to further aspects of the invention, lack of certain MLO genes is used as markers for pathogen resistance and may accelerate breeding for more resistant Cannabis lines.

According to one embodiment, the present invention provides a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein said modified plant comprises a mutated Cannabis mlol (Csmlol) allele, said mutated allele comprising a genomic modification selected from an indel of 14 bp at position corresponding to position 12 of SEQ ID NO: 882, or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof.

According to a further embodiment of the present invention, the indel comprises a sequence as set forth in SEQ ID NO:883 or a fraction thereof.

According to a further embodiment of the present invention, the Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele, or a complementary sequence thereof, or any combination thereof.

According to a further embodiment of the present invention, the Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele.

According to a further embodiment of the present invention, the mutated Csmlol allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele having a nucleic acid sequence as set forth in SEQ ID NO:882 and/or having a nucleic acid sequence as set forth in SEQ ID NO:1 or a functional variant thereof.

According to a further embodiment of the present invention, the functional variant has at least 80% sequence identity to the corresponding CsMLO1 nucleotide sequence.

According to a further embodiment of the present invention, the mutated allele comprising a deletion of 14 bp at position 389 of SEQ ID NO: 1, or a nucleic acid insertion at position 482-483 of SEQ ID NO: 1, or a combination thereof.

According to a further embodiment of the present invention, the mutated Csmlol allele is generated using genome editing.

It is further within the scope of the present invention to provide, a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein said modified plant comprises a targeted genome modification conferring reduced expression of a Cannabis MLO1 (CsMLO1) gene as compared to a Cannabis plant lacking said targeted genome modification, said targeted genome modification generates a mutated Cannabis mlol (Csmlol) allele comprising a deletion of a nucleic acid sequence as set forth in SEQ ID NO:883 or a fraction thereof as compared to the wild type CsMLO1 allele comprising a sequence as set forth in SEQ ID NO:1, or a nucleic acid insertion at position 482-483 of SEQ ID NO:1, or a combination thereof.

According to a further aspect of the present invention, a method for producing a modified Cannabis plant as defined in any of the above is provided. The method comprises introducing using targeted genome modification, at least one genomic modification conferring reduced expression of at least one Cannabis MLO1 (CsMLO1) allele as compared to a Cannabis plant lacking said targeted genome modification, said genomic modification generates a mutated Cannabis mlol (Csmlol) allele comprising an indel of 14 bp at a position corresponding to position 12 of SEQ ID NO: 882 or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof.

According to further aspects of the present invention, a method of determining the presence of a mutant Csmlol allele in a Cannabis plant is provided. The method comprising assaying the Cannabis plant for at least one of the presence of an indel comprising a nucleic acid sequence as set forth in SEQ ID NO:883, an insertion at position 104-105 of SEQ ID NO: 882, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele, a complementary sequence thereof, or any combination thereof.

It is further within the scope to provide a method for identifying a Cannabis plant with resistance to powdery mildew, said method comprises steps of: (a) screening the genome of said Cannabis plant for a mutated Csmlol allele, said mutated allele comprises a genomic modification selected from an indel of 14 bp at a position corresponding to position 12 of SEQ ID NO: 882 or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof; (b) optionally, regenerating plants carrying said genetic modification; and (c) optionally, screening said regenerated plants for a plant resistant to powdery mildew.

It is further within the scope of the present invention to provide a method for down regulation of Cannabis MLO1 (CsMLO1) gene, which comprises utilizing the nucleotide sequence as set forth in at least one of SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, and a combination thereof, for introducing a loss of function mutation into said CsMLO1 gene using targeted genome modification.

The present invention further provides an isolated amino acid sequence having at least 80% sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:882-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof.

It is also within the scope to disclose a use of a nucleotide sequence as set forth in SEQ ID NO: 883-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 for generating, identifying and/or screening for a Cannabis plant comprising within its genome mutant Csmlo allele conferring resistance to PM.

It is also within the scope to disclose a use of a nucleotide sequence as set forth in at least one of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof for targeted genome modification of Cannabis MLO1 (CsMLO1) gene.

According to further aspects, the present invention provides a detection kit for determining the presence or absence of a mutant Csmlol allele in a Cannabis plant, comprising a nucleic acid fragment comprising a sequence selected from SEQ ID NO:882-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof.

According to an embodiment of the present invention, the targeted genome modification is in a CsMLO allele having a wild type genomic nucleotide sequence selected from the group consisting of CsMLO1 having a sequence as set forth in SEQ ID NO:1 or a functional variant thereof, CsMLO2 having a sequence as set forth in SEQ ID NO:4 or a functional variant thereof and CsMLO3 having a sequence as set forth in SEQ ID NO:7 or a functional variant thereof.

According to a further embodiment of the present invention, the functional variant has at least %, preferably 80% sequence identity to the corresponding CsMLO nucleotide sequence.

According to a further embodiment of the present invention, the modified Cannabis plant has decreased expression levels of at least one Mlo protein, relative to a Cannabis plant lacking the at least one genome modification.

According to a further embodiment of the present invention, the genome modification is introduced using mutagenesis, small interfering RNA (siRNA), microRNA (miRNA), artificial miRNA (amiRNA), DNA introgression, endonucleases or any combination thereof.

According to a further embodiment of the present invention, the genetic modification is introduced using targeted genome modification, preferably said genetic modification is introduced using an endonuclease.

According to a further embodiment of the present invention, the genome modification is introduced using guide RNA, e.g. single guide RNA (sgRNA) designed and targeted to mutate CsMLO1 gene, said sgRNA nucleotide sequence is selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50.

According to a further embodiment of the present invention, the modified Cannabis plant comprises at least one mutated CsMLO1 allele comprising a nucleotide sequence selected from the group consisting of a nucleotide sequence as set forth in SEQ ID NO:875, a nucleotide sequence as set forth in SEQ ID NO:877, a nucleotide sequence as set forth in SEQ ID NO:880 or a homologue having at least 80% sequence identity to the nucleotide sequence of said at least one mutated CsMLO1 allele or a combination thereof.

According to a further embodiment of the present invention, the modified Cannabis plant comprises at least one silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation or any combination thereof in at least one gene or allele selected from the group consisting of CsMLO1, CsMLO2 and CsMLO3.

According to a further embodiment of the present invention the mutated CsMLO1 allele comprises a deletion having a nucleotide sequence as set forth in SEQ ID NO.:876, SEQ ID NO.:879 or SEQ ID NO.:881.

According to a further embodiment of the present invention, the mutated CsMLO1 allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele sequence.

According to a further embodiment of the present invention, the wild type CsMLO1 allele comprises a nucleic acid sequence as set forth in at least one of SEQ ID NO:873, SEQ ID NO:876, SEQ ID NO:879 or SEQ ID NO:881. According to a further embodiment of the present invention the present invention provides modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM) compared to wild type Cannabis plant, wherein the modified plant comprises a genetic modification conferring reduced expression of at least one Cannabis MLO (CsMLO) allele. The present invention further provides methods for producing the aforementioned modified Cannabis plant using genome editing or modification techniques.

Powdery mildew (PM) is a major fungal disease that threatens thousands of plant species. Powdery mildew is commonly controlled by frequent applications of fungicides, having negative effects on the environment, and leading to additional costs for growers. To reduce the amount of chemicals required to control this pathogen, the development of resistant crop varieties is a priority.

It is herein acknowledged that PM pathogenesis is associated with up-regulation of specific MLO genes during early stages of infection, causing down-regulation of plant defense pathways. These up-regulated genes are responsible for PM susceptibility (S-genes) and their knock-out cause durable and broad-spectrum resistance.

As the Cannabis legal market is expanding worldwide, this agricultural crop will gradually move from indoor growing facilities to simple low cost greenhouses to enable mass production at reduced operational costs. One of the major challenges facing this transition is the lack of compatible genetics (strains) adapted for green house growth and more specifically genetic fungal resistances. Cannabis susceptibility to fungal diseases results in damages and losses to the grower and forces the widespread use of fungicides. Excessive fungicide use poses health threats to Cannabis consumers.

To date, there are no fungal disease resistant Cannabis varieties on the market. Classical breeding programs dedicated to the end of creating fungal disease resistant Cannabis varieties are virtually impossible due to limited genetic variation, legal constraints on import and export of genetic material and limited academic knowledge and gene banks involved is such projects. In addition, traditional breeding is a long process with low rates of success and certainty, as it is based on trial and error.

The solution proposed by the current invention is using genome editing such as the CRISPR/Cas system in order to create fungal disease resistant Cannabis varieties. Breeding using genome editing allows a precise and significantly shorter breeding process in order to achieve these goals with a much higher success rate. Thus genome editing, has the potential to generate improved varieties faster and at a lower cost. By using genome editing to generate Powdery Mildew (PM) resistant Cannabis varieties, the current disclosure will allow growers worldwide to supply a safer product to Cannabis consumers.

It is further noted that using genome editing is considered as non GMO by the Israeli regulator and in the US, the USDA has already classified a dozen of genome edited plant as non regulated and non GMO (https://www.usda.gov/media/press-releases/2018/03/28/secretary-perdue-issues-usda statement-plant-breeding-innovation).

The Cannabis industry's value chain is based on a steady supply of high quality consistent product. Due to lack of suitable genetics adapted for intensive agriculture production, most growing methods are based on cloning as a mean of vegetative propagation in order to ensure genetic consistency of the plant material. These methods are outdated, expensive and not fit for purpose. The lack of Cannabis strains that are disease resistant, stable and uniform, pose a threat to the ability of supplying the industry with the raw material needed to support itself.

Legal limitations and outdated breeding techniques significantly hamper the efforts of generating new and improved Cannabis varieties fit for intensive agriculture.

Cannabis legalization in certain countries has increased significantly the number of Cannabis growers and area used for growing. One possible solution is moving growing Cannabis into greenhouses (protected growing facilities) like the vegetable industry has been doing for the last few decades. Unlike the vegetable industry, Cannabis is based on vegetative propagation while vegetables are grown through seeds. In addition, Cannabis growers are using Cannabis strains that were bred for indoor cultivation and are now using those for their greenhouse operations. This situation is obviously not ideal and causes many logistic issues for the growers. For example, since Cannabis plants require short days for the induction of flowering, growers install darkening curtains in the greenhouse to control day length for the plants. This artificial darkening results in increased humidity in the greenhouse thus creating optimal conditions for fungal pathogens to spread and thrive. These conditions force growers to intensively use fungicides to control pathogen populations. With strict regulatory constraints in place across the legalized states, these conditions pose a great challenge for sustainable Cannabis production and consumer health.

The next step for the Cannabis industry is the adoption and use of hybrid seeds for propagation, which is common practice in the conventional seed industry (from field crops to vegetables). In addition, breeding for basic agronomic traits that are completely lacking in currently available Cannabis varieties (with an emphasis on disease resistances) will significantly increase grower's productivity. This will allow growing and supplying high quality raw material for the Cannabis industry.

In order to generate a reproducible product, Cannabis growers are currently using vegetative propagation (cloning or tissue culture). However, in conventional agricultural, genetic stability of field crops and vegetables is maintained by using F1 hybrid seeds. These hybrids are generated by crossing homozygous parental lines.

Currently, breeding of Cannabis plants is mostly done by small Cannabis growers. There is very limited if any molecular tools supporting or leading the breeding process. Traditional Cannabis breeding is done by mixing breeding material with hope to find the desired traits and phenotypes by random crosses.

The present invention provides for the first time enhanced resistant Cannabis plants to fungal diseases. The current invention disclose the generation of non-transgenic Cannabis plant resistant to the powdery mildew fungal disease, using the genome editing technology, e.g., the

CRISPR/Cas9 tool. The generated mutations can be readily introduced into elite or locally adapted Cannabis lines rapidly, with relatively minimal effort and investment.

As used herein the term "about" denotes 25% of the defined amount or measure or value.

As used herein the term "similar" denotes a correspondence or resemblance range of about %, particularly 15%, more particularly about 10% and even more particularly about 5%.

A "plant" as used herein refers to any plant at any stage of development, particularly a seed plant. The term "plant" includes the whole plant or any parts or derivatives thereof, such as plant cells, seeds, plant protoplasts, plant cell tissue culture from which tomato plants can be regenerated, plant callus or calli, meristematic cells, microspores, embryos, immature embryos, pollen, ovules, anthers, fruit, flowers, leaves, cotyledons, pistil, seeds, seed coat, roots, root tips and the like.

The term "plant cell" used herein refers to a structural and physiological unit of a plant, comprising a protoplast and a cell wall. The plant cell may be in a form of an isolated single cell or a cultured cell, or as a part of higher organized unit such as, for example, plant tissue, a plant organ, or a whole plant.

The term "plant cell culture" as used herein means cultures of plant units such as, for example, protoplasts, regenerable cells, cell culture, cells, cells in plant tissues, pollen, pollen tubes, ovules, embryo sacs, zygotes and embryos at various stages of development, leaves, roots, root tips, anthers, meristematic cells, microspores, flowers, cotyledons, pistil, fruit, seeds, seed coat or any combination thereof.

The term "plant material" or "plant part" used herein refers to leaves, stems, roots, root tips, flowers or flower parts, f uits, pollen, egg cells, zygotes, seeds, seed coat, cuttings, cell or tissue cultures, or any other part or product of a plant or a combination thereof.

A "plant organ" as used herein means a distinct and visibly structured and differentiated part of a plant such as a root, stem, leaf, flower, flower bud, or embryo.

The term "Plant tissue" as used herein means a group of plant cells organized into a structural and functional unit. Any tissue of a plant in planta or in culture is included. This term includes, but is not limited to, whole plants, plant organs, plant seeds, tissue culture, protoplasts, meristematic cells, calli and any group of plant cells organized into structural and/or functional units. The use of this term in conjunction with, or in the absence of, any specific type of plant tissue as listed above or otherwise embraced by this definition is not intended to be exclusive of any other type of plant tissue.

As used herein, the term "progeny" or "progenies" refers in a non limiting manner to offspring or descendant plants. According to certain embodiments, the term "progeny" or "progenies" refers to plants developed or grown or produced from the disclosed or deposited seeds as detailed inter alia. The grown plants preferably have the desired traits of the disclosed or deposited seeds, i.e. reduced expression of at least one CsMLO gene.

The term "Cannabis"refers hereinafter to a genus of flowering plants in the family Cannabaceae. Cannabis is an annual, dioecious, flowering herb that includes, but is not limited to three different species, Cannabis sativa, Cannabisindica and Cannabisruderalis.The term also refers to hemp. Cannabis plants produce a group of chemicals called cannabinoids. Cannabinoids, terpenoids, and other compounds are secreted by glandular trichomes that occur most abundantly on the floral calyxes and bracts of female Cannabis plants.

As used herein the term "genetic modification" or "genomic modification" refers hereinafter to genetic manipulation or modulation, which is the manipulation of an organism's genes using biotechnology. It also refers to a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species, targeted mutagenesis and genome editing technologies to produce improved organisms. According to main embodiments of the present invention, modified Cannabis plants with increased resistance to PM are generated using genome editing mechanism. This technique enables to achieve in planta modification of specific genes that relate to and/or control the infection of powdery mildew in the Cannabis plant.

The term "genome editing", or "genome/genetic modification" or "genome engineering" generally refers hereinafter to a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike previous genetic engineering techniques that randomly insert genetic material into a host genome, genome editing targets the insertions to site specific locations.

It is within the scope of the present invention that the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations ('edits'). Families of engineered nucleases used by the current invention include, but are not limited to: meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system.

Reference is now made to exemplary genome editing terms used by the current disclosure:

Genome Editing Glossary

Cas = CRISPR-associated genes Indel= insertion and/or deletion Cas9, Csn1 = a CRISPR-associated protein NHEJ= Non-Homologous End joining containing two nuclease domains, that is PAM =Protospacer-Adjacent Motif programmed by small RNAs to cleave DNA RuvC =anendonuclease domain named for crRNA = CRISPR RNA an E coliprotein involved in DNA repair dCAS9 = nuclease-deficient Cas9 sgRNA = single guide RNA DSB = Double-Stranded Break tracrRNA, trRNA = trans-activating crRNA gRNA = guide RNA TALEN = Transcription-Activator Like HDR = Homology-Directed Repair Effector Nuclease HNH = an endonuclease domain named ZFN = Zinc-Finger Nuclease for characteristic histidine and asparagine residues

It is noted that it is within the scope of the current invention that the term gRNA also refers to or means single guide RNA (sgRNA).

According to specific aspects of the present invention, the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are used for the first time for generating genome modification in targeted genes in the Cannabis plant. It is herein acknowledged that the functions of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are essential in adaptive immunity in select bacteria and archaea, enabling the organisms to respond to and eliminate invading genetic material. These repeats were initially discovered in the 1980s in E. coli. Without wishing to be bound by theory, reference is now made to a type of CRISPR mechanism, in which invading DNA from viruses or plasmids is cut into small fragments and incorporated into a CRISPR locus comprising a series of short repeats (around 20 bps). The loci are transcribed, and transcripts are then processed to generate small RNAs (crRNA, namely CRISPR RNA), which are used to guide effector endonucleases that target invading DNA based on sequence complementarity.

According to further aspects of the invention, Cas protein, such as Cas9 (also known as Csnl) is required for gene silencing. Cas9 participates in the processing of crRNAs, and is responsible for the destruction of the target DNA. Cas9's function in both of these steps relies on the presence of two nuclease domains, a RuvC-like nuclease domain located at the amino terminus and a HNH like nuclease domain that resides in the mid-region of the protein. To achieve site-specific DNA recognition and cleavage, Cas9 is complexed with both a crRNA and a separate trans-activating crRNA (tracrRNA or trRNA), that is partially complementary to the crRNA. The tracrRNA is required for crRNA maturation from a primary transcript encoding multiple pre-crRNAs. This occurs in the presence of RNase III and Cas9.

Without wishing to be bound by theory, it is herein acknowledged that during the destruction of target DNA, the HNH and RuvC-like nuclease domains cut both DNA strands, generating double stranded breaks (DSBs) at sites defined by a 20-nucleotide target sequence within an associated crRNA transcript. The HNH domain cleaves the complementary strand, while the RuvC domain cleaves the noncomplementary strand.

It is further noted that the double-stranded endonuclease activity of Cas9 also requires that a short conserved sequence, (2-6 nucleotides) known as protospacer-associated motif (PAM), follows immediately 3'- of the crRNA complementary sequence.

According to further aspects of the invention, a two-component system may be used by the current invention, combining trRNA and crRNA into a single synthetic single guide RNA (sgRNA) for guiding targeted gene alterations.

It is further within the scope that Cas9 nuclease variants include wild-type Cas9, Cas9D1OA and nuclease-deficient Cas9 (dCas9).

Reference is now made to Fig. 3 schematically presenting an example of CRISPR/Cas9 mechanism of action as depicted by Xie, Kabin, and Yinong Yang. "RNA-guided genome editing in plants using a CRISPR-Cas system." Molecularplant6.6 (2013): 1975-1983. As shown in this figure, the Cas9 endonuclease forms a complex with a chimeric RNA (called guide RNA or gRNA), replacing the crRNA-transcrRNA heteroduplex, and the gRNA could be programmed to target specific sites. The gRNA-Cas9 should comprise at least 15-base-pairing (gRNA seed region) without mismatch between the 5'-end of engineered gRNA and targeted genomic site, and a motif called protospacer-adjacent motif or PAM that follows the base-pairing region in the complementary strand of the targeted DNA. The commonly-used Cas9 from Streptococcus pyogenes (SpCas9) recognizes the PAM sequence 5'-NGG-3' (where "N" can be any nucleotide base).

Other Cas variants and their PAM sequences (5' to 3') within the scope of the current invention include NmeCas9 (isolated from Neisseria meningitides) recognizing NNNNGATT, StCas9 (isolated from Streptococcus thermophiles) recognizing NNAGAAW, TdCas9 (isolated from Treponema denticola) recognizing NAAAAC, SaCas9 (isolated from Staphylococcus aureus) recognizing NNGRRT or NGRRT or NGRRN and TBN (Cas-phi).

The term "meganucleases" as used herein refers hereinafter to endodeoxyribonucleases characterized by a large recognition site (double-stranded DNA sequences of 12 to 40 base pairs); as a result this site generally occurs only once in any given genome. Meganucleases are therefore considered to be the most specific naturally occurring restriction enzymes.

The term "protospacer adjacent motif" or "PAM" as used herein refers hereinafter to a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease in the CRISPR bacterial adaptive immune system. PAM is a component of the invading virus or plasmid, but is not a component of the bacterial CRISPR locus. PAM is an essential targeting component which distinguishes bacterial self from non-self DNA, thereby preventing the CRISPR locus from being targeted and destroyed by nuclease.

The term "Next-generation sequencing" or "NGS" as used herein refers hereinafter to massively, parallel, high- throughput or deep sequencing technology platforms that perform sequencing of millions of small fragments of DNA in parallel. Bioinformatics analyses are used to piece together these fragments by mapping the individual reads to the reference genome.

The term "gene knockdown" as used herein refers hereinafter to an experimental technique by which the expression of one or more of an organism's genes is reduced. The reduction can occur through genetic modification, i.e. targeted genome editing or by treatment with a reagent such as a short DNA or RNA oligonucleotide that has a sequence complementary to either gene or an mRNA transcript. The reduced expression can be at the level of RNA or at the level of protein. It is within the scope of the present invention that the term gene knockdown also refers to a loss of function mutation and /or gene knockout mutation in which an organism's genes is made inoperative or nonfunctional.

The term "gene silencing" or "silence" or silencing" as used herein refers hereinafter to the regulation of gene expression in a cell to prevent the expression of a certain gene. Gene silencing can occur during either transcription or translation. In certain aspects of the invention, gene silencing is considered to have a similar meaning as gene knockdown. When genes are silenced, their expression is reduced. In contrast, when genes are knocked out, they are completely not expressed. Gene silencing may be considered a gene knockdown mechanism since the methods used to silence genes, such as RNAi, CRISPR, or siRNA, generally reduce the expression of a gene by at least 70% but do not completely eliminate it. In some embodiments of the present invention, gene silencing by targeted genome modification results in non-functional gene products, such as transcripts or proteins, for example non-functional CsMLO1 exon 1 fragments.

The term "microRNAs" or "miRNAs" refers hereinafter to small non-coding RNAs that have been found in most of the eukaryotic organisms. They are involved in the regulation of gene expression at the post-transcriptional level in a sequence specific manner. MiRNAs are produced from their precursors by Dicer-dependent small RNA biogenesis pathway. MiRNAs are candidates for studying gene function using different RNA-based gene silencing techniques. For example, artificial miRNAs (amiRNAs) targeting one or several genes of interest is a potential tool in functional genomics.

The term "inplanta" means in the context of the present invention within the plant or plant cells. More specifically, it means introducing CRISPR/Cas complex into plant material comprising a tissue culture of several cells, a whole plant, or into a single plant cell, without introducing a foreign gene or a mutated gene. It also used to describe conditions present in a non-laboratory environment (e.g. in vivo).

As used herein, the term "powdery mildew" or "PM" refers hereinafter to fungi that are obligate, biotrophic parasites of the phylum Ascomycota of Kingdom Fungi. The diseases they cause are common, widespread, and easily recognizable. Infected plants display white powdery spots on the leaves and stems Infection by the fungus is favored by high humidity but not by free water. Powdery mildew fungi tend to grow superficially, or epiphytically, on plant surfaces. During the growing season, hyphae are produced preferably on both upper and lower leaf surfaces. Infections can also occur on stems, flowers, or fruit. Specialized absorption cells, termed haustoria, extend into the plant epidermal cells to obtain nutrition.

Powdery mildew fungi can reproduce both sexually and asexually. Sexual reproduction is via chasmothecia (cleistothecium), a type of ascocarp where the genetic material recombines. Within each ascocarp are several asci. Under optimal conditions, ascospores mature and are released to initiate new infections Conidia (asexual spores) are also produced on plant surfaces during the growing season. They develop either singly or in chains on specialized hyphae called conidiophores. Conidiophores arise from the epiphytic hyphae, or in the case of endophytic hyphae, the conidiophores emerge through leaf stomata. It should be noted that powdery mildew fungi must be adapted to their hosts to be able to infect them. The present invention provides for the first time Cannabis plants with enhanced resistance or tolerance to PM disease. The enhanced resistance to PM is generated by genome editing techniques targeted at silencing at least one Cannabis Mildew Locus 0 (MLO) gene. The modified resulted Cannabis plant exhibits enhanced resistance to PM as compared to a Cannabis plant lacking the targeted modification.

The term "MLO" or "Mlo" or "mo" refers hereinafter to the Mildew Locus 0 (MLO) gene family encoding for plant-specific proteins harboring several transmembrane domains, topologically reminiscent of metazoan G-protein coupled receptors. It is within the scope of the present invention that specific homologs of the MLO family act as susceptibility genes towards PM fungi. It is emphasized that the present invention provides for the first time the identification of MLO orthologous alleles in the Cannabis plant. Three Cannabis MLO alleles or genes (i.e. MLO1, MLO2, MLO3) have been herein identified, namely CsMLO1, CsMLO2 and CsMLO3.

The term "orthologue" as used herein refers hereinafter to one of two or more homologous gene sequences found in different species.

The term "functional variant" or "functional variant of a nucleic acid or protein sequence" as used herein, for example with reference to SEQ ID NOs: 1, 2 or 3 refers to a variant gene sequence or part of the gene sequence which retains the biological function of the full non-variant allele (e.g.

CsMLO allele) and hence has the activity of modulating response to PM. A functional variant also comprises a variant of the gene of interest encoding a polypeptide which has sequence alterations that do not affect function of the resulting protein, for example in non-conserved residues. Also encompassed is a variant that is substantially identical, i.e. has only some sequence variations, for example in non-conserved residues, to the wild type nucleic acid sequences of the alleles as shown herein and is biologically active.

The term "variety" or "cultivar" used herein means a group of similar plants that by structural features and performance can be identified from other varieties within the same species.

The term "allele" used herein means any of one or more alternative or variant forms of a gene or a genetic unit at a particular locus, all of which alleles relate to one trait or characteristic at a specific locus. In a diploid cell of an organism, alleles of a given gene are located at a specific location, or locus (loci plural) on a chromosome. Alternative or variant forms of alleles may be the result of single nucleotide polymorphisms, insertions, inversions, translocations or deletions, or the consequence of gene regulation caused by, for example, by chemical or structural modification, transcription regulation or post-translational modification/regulation. An allele associated with a qualitative trait may comprise alternative or variant forms of various genetic units including those mat are identical or associated with a single gene or multiple genes or their products or even a gene disrupting or controlled by a genetic factor contributing to the phenotype represented by the locus. According to further embodiments, the term "allele" designates any of one or more alternative forms of a gene at a particular locus. Heterozygous alleles are two different alleles at the same locus. Homozygous alleles are two identical alleles at a particular locus. A wild type allele is a naturally occurring allele. In the context of the current invention, the term allele refers to the three identified Cannabis MLO genes, namely CsMLO1, CsMLO2 and CsMLO3 having the genomic nucleotide sequence as set forth in SEQ ID NOs: 1, 2 or 3, respectively.

As used herein, the term "locus" (loci plural) means a specific place or places or region or a site on a chromosome where for example a gene or genetic marker element or factor is found. In specific embodiments, such a genetic element is contributing to a trait.

As used herein, the term "homozygous" refers to a genetic condition or configuration existing when two identical or like alleles reside at a specific locus, but are positioned individually on corresponding pairs of homologous chromosomes in the cell of a diploid organism.

Conversely, as used herein, the term "heterozygous" means a genetic condition or configuration existing when two different or unlike alleles reside at a specific locus, but are positioned individually on corresponding pairs of homologous chromosomes in the cell of a diploid organism. In specific embodiments, the tomato plants of the present invention comprise heterozygous configuration of the genetic markers associated with the high yield characteristics.

The term "corresponding" or "corresponding to" or "corresponding to nucleotide sequence" or "corresponding to position" as used herein, refers in the context of the present invention to sequence homology or sequence identity. These terms relate to two or more nucleic acid or protein sequences, that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the available sequence comparison algorithms or by visual inspection. If two sequences, which are to be compared with each other, differ in length, sequence identity preferably relates to the percentage of the nucleotide residues of the shorter sequence, which are identical with the nucleotide residues of the longer sequence. As used herein, the percent of identity or homology between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of identity percent between two sequences can be accomplished using a mathematical algorithm as known in the relevant art. According to further aspects of the invention, the term "corresponding to the nucleotide sequence" or "corresponding to position", refers to variants, homologues and fragments of the indicated nucleotide sequence, which possess or perform the same biological function or correlates with the same phenotypic characteristic of the indicated nucleotide sequence.

Another indication that two nucleic acid sequences are substantially identical or that a sequence is "corresponding to the nucleotide sequence" is that the two molecules hybridize to each other under stringent conditions. High stringency conditions, such as high hybridization temperature and low salt in hybridization buffers, permits only hybridization between nucleic acid sequences that are highly similar, whereas low stringency conditions, such as lower temperature and high salt, allows hybridization when the sequences are less similar.

In other embodiments of the invention, such substantially identical sequences refer to polynucleotide or amino acid sequences that share at least about 80% similarity, preferably at least about 90% similarity, alternatively, about 95%, 96%, 97%, 98% or 99% similarity to the indicated polynucleotide or amino acid sequences.

According to other aspects of the invention, the term "corresponding" refers also to complementary sequences or base pairing such that when they are aligned antiparallel to each other, the nucleotide bases at each position in the sequences will be complementary. The degree of complementarity between two nucleic acid strands may vary.

As used herein, the phrase "genetic marker" or "molecular marker" or "biomarker" refers to a feature in an individual's genome e.g., a nucleotide or a polynucleotide sequence that is associated with one or more loci or trait of interest In some embodiments, a genetic marker is polymorphic in a population of interest, or the locus occupied by the polymorphism, depending on context. Genetic markers or molecular markers include, for example, single nucleotide polymorphisms (SNPs), indels (i.e. insertions deletions), simple sequence repeats (SSRs), restriction fragment length polymorphisms (RFLPs), random amplified polymorphic DNAs (RAFDs), cleaved amplified polymorphic sequence (CAPS) markers, Diversity Arrays Technology (DArT) markers, and amplified fragment length polymorphisms (AFLPs) or combinations thereof, among many other examples such as the DNA sequence per se. Genetic markers can, for example, be used to locate genetic loci containing alleles on a chromosome that contribute to variability of phenotypic traits. The phrase "genetic marker" or "molecular marker" or "biomarker" can also refer to a polynucleotide sequence complementary or corresponding to a genomic sequence, such as a sequence of a nucleic acid used as a probe or primer.

As used herein, the term "germplasm" refers to the totality of the genotypes of a population or other group of individuals (e.g., a species). The term "germplasm" can also refer to plant material; e.g., a group of plants that act as a repository for various alleles. Such germplasm genotypes or populations include plant materials of proven genetic superiority; e.g., for a given environment or geographical area, and plant materials of unknown or unproven genetic value; that are not part of an established breeding population and that do not have a known relationship to a member of the established breeding population.

The terms "hybrid", "hybrid plant" and "hybrid progeny" used herein refers to an individual produced from genetically different parents (e.g., a genetically heterozygous or mostly heterozygous individual).

As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins, it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. The term further refers hereinafter to the amount of characters which match exactly between two different sequences. Hereby, gaps are not counted and the measurement is relational to the shorter of the two sequences.

It is further within the scope that the terms "similarity" and "identity" additionally refer to local homology, identifying domains that are homologous or similar (in nucleotide and/or amino acid sequence). It is acknowledged that bioinformatics tools such as BLAST, SSEARCH, FASTA, and HMMER calculate local sequence alignments which identify the most similar region between two sequences. For domains that are found in different sequence contexts in different proteins, the alignment should be limited to the homologous domain, since the domain homology is providing the sequence similarity captured in the score. According to some aspects the term similarity or identity further includes a sequence motif, which is a nucleotide or amino-acid sequence pattern that is widespread and has, or is conjectured to have, a biological significance. Proteins may have a sequence motif and/or a structural motif, a motif formed by the three- dimensional arrangement of amino acids which may not be adjacent.

As used herein, the terms "nucleic acid", "nucleic acid sequence", "nucleotide", "nucleic acid molecule" or "polynucleotide" are intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), natural occurring, mutated, synthetic DNA or RNA molecules, and analogs of the DNA or RNA generated using nucleotide analogs. It can be single stranded or double-stranded. Such nucleic acids or polynucleotides include, but are not limited to, coding sequences of structural genes, anti-sense sequences, and non-coding regulatory sequences that do not encode mRNAs or protein products. These terms also encompass a gene. The term "gene", "allele" or "gene sequence" is used broadly to refer to a DNA nucleic acid associated with a biological function. Thus, genes may include introns and exons as in the genomic sequence, or may comprise only a coding sequence as in cDNAs, and/or may include cDNAs in combination with regulatory sequences. Thus, according to the various aspects of the invention, genomic DNA, cDNA or coding DNA may be used. In one embodiment, the nucleic acid is cDNA or coding DNA.

The terms "peptide", "polypeptide" and "protein" are used interchangeably herein and refer to amino acids in a polymeric form of any length, linked together by peptide bonds.

According to other aspects of the invention, a 'modified" or a "mutant" plant is a plant that has been altered compared to the naturally occurring wild type (WT) plant. Specifically, the endogenous nucleic acid sequences of each of the MLO homologs in Cannabis (nucleic acid sequences CsMLO1, CsMLO2 and CsMLO3) have been altered compared to wild type sequences using mutagenesis and/or genome editing methods as described herein. This causes inactivation of the endogenous Mlo genes and thus disables Mlo function. Such plants have an altered phenotype and show resistance or increased resistance to PM compared to wild type plants. Therefore, the resistance is conferred by the presence of at least one mutated endogenous CsMLO1, CsMLO2 and CsMLO3 genes in the Cannabis plant genome which has been specifically targeted using targeted genome modification.

According to further aspects of the present invention, the increased resistance to PM is not conferred by the presence of transgenes expressed in Cannabis.

It should be noted that nucleic acid sequences of wild type alleles are designated using capital letters namely CsMLO1, CsMLO2 and CsMLO3. Mutant mlo nucleic acid sequences use non capitalization. Cannabis plants of the invention are modified plants compared to wild type plants which comprise and express mutant mlo alleles.

It is further within the scope of the current invention that mlo mutations that down-regulate or disrupt functional expression of the wild-type Mlo sequence may be recessive, such that they are complemented by expression of a wild-type sequence.

A mlo mutant phenotype according to the invention is characterized by the exhibition of an increased resistance against PM. In other words, a mlo mutant according to the invention confers resistance to the pathogen causing PM, which is identified as described inter alia.

It is further noted that a wild type Cannabis plant is a plant that does not have any mutant Mlo alleles.

Main aspects of the invention involve targeted mutagenesis methods, specifically genome editing, and exclude embodiments that are solely based on generating plants by traditional breeding methods. In a further embodiment of the current invention, as explained herein, the disease resistant trait is not due to the presence of a transgene.

The inventors have generated mutant Cannabis lines with mutations inactivating at least one CsMLO homoeoallele which confer heritable resistance to powdery mildew. In this way no functional CsMLO protein is made. Thus, the invention relates to these mutant Cannabis lines and related methods.

According to one embodiment, the present invention provides a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM) compared to wild type Cannabis plant. The Cannabis plant of the present invention comprises a genetic modification conferring reduced expression of at least one Cannabis MLO (CsMLO) allele.

It is within the scope of the present invention that the CsMLO allele is selected from the group consisting of CsMLO1 having a nucleotide sequence as set forth in SEQ ID NO:1 or a fragment or a functional variant thereof, CsMLO2 having a nucleotide sequence as set forth in SEQ ID NO:4 or a fragment or a functional variant thereof and CsMLO3 having a nucleotide sequence as set forth in SEQ ID NO:7 or a fragment or a functional variant thereof.

According to a further embodiment of the present invention, the functional variant has at least 75% sequence identity to the CsMLO nucleotide sequence.

It is within the scope of the current invention that genome editing can be achieved using sequence specific nucleases (SSNs) and results in chromosomal changes, such as nucleotide deletions, insertions or substitutions at specified genetic loci. Non limiting examples of SSNs include zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs) and, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) system.

Non limiting examples Cas proteins used by the present invention include Csn1, Cpfl Cas9, Cas12, Cas13, Cas14, CasX and any combination thereof.

According to further aspects of the invention, Cannabis plant resistant to the powdery mildew fungal pathogen using the CRISPR/Cas9 technology is generated, which is based on the Cas9 DNA nuclease guided to a specific DNA target by a single guide RNA (sgRNA).

It is herein acknowledged that wild-type alleles of MILDEW RESISTANT LOCUS 0 (Mlo), which encodes a membrane-associated protein with seven transmembrane domains, confer susceptibility to fungi causing the powdery mildew disease. Therefore, homozygous loss-of function mutations (mlo) result in resistance to powdery mildew.

According to certain embodiments of the present invention, in planta modification of specific genes that relate to and/or control the infection of powdery mildew in the Cannabis plant is achieved for the first time by the present invention, i.e. the Cannabis MLO genes (CsMLO). More specifically, but not limited to, the use of gene editing technologies, for example the CRISPR/Cas technology (e.g. Cas9 or Cpfl), in order to generate knockout alleles of genes (i.e. MLO genes) controlling the resistance to powdery mildew (PM) is disclosed for the Cannabis plant. The above in planta modification can be based on alternative gene editing technologies such as Zinc Finger Nucleases (ZFN's), Transcription activator-like effector nucleases (TALEN's), RNA silencing (amiRNA etc.) and/or meganucleases.

The loss of function mutation may be a deletion or insertion ("indels") with reference the wild type CsMLO allele sequence. The deletion may comprise 1-20 or more, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18 or 20 nucleotides or more in one or more strand. The insertion may comprise 1-20 or more, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18 or or more nucleotides in one or more strand.

The plant of the invention includes plants wherein the plant is heterozygous for the each of the mutations. In a preferred embodiment however, the plant is homozygous for the mutations. Progeny that is also homozygous can be generated from these plants according to methods known in the art.

It is further within the scope that variants of a particular CsMLO nucleotide or amino acid sequence according to the various aspects of the invention will have at least about 50%-99%, for example at least 75%, for example at least 85%, 86%, 87%, 88%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to that particular non-variant CsMLO nucleotide sequence of the CsMLO allele as shown in SEQ ID NO 1, 2 or 3. Sequence alignment programs to determine sequence identity are well known in the art.

Also, the various aspects of the invention encompass not only a CsMLO nucleic acid sequence or amino acid sequence, but also fragments thereof. By "fragment" is intended a portion of the nucleotide sequence or a portion of the amino acid sequence and hence of the protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence act to modulate responses to PM.

According to a further embodiment of the invention, the herein newly identified Cannabis MLO locus (CsMLO) have been targeted using the triple sgRNA strategy.

According to further embodiments of the present invention, DNA introduction into the plant cells can be done by Agrobacterium infiltration, virus based plasmids for delivery of the genome editing molecules and mechanical insertion of DNA (PEG mediated DNA transformation, biolistics, etc.).

In addition, it is within the scope of the present invention that the Cas9 protein is directly inserted together with a gRNA (ribonucleoprotein- RNP's) in order to bypass the need for in vivo transcription and translation of the Cas9+gRNA plasmid in planta to achieve gene editing.

It is also possible to create a genome edited plant and use it as a rootstock. Then, the Cas protein and gRNA can be transported via the vasculature system to the top of the plant and create the genome editing event in the scion.

It is within the scope of the present invention that the usage of CRISPR/Cas system for the generation of PM resistant Cannabis plants, allows the modification of predetermined specific DNA sequences without introducing foreign DNA into the genome by GMO techniques. According to one embodiment of the present invention, this is achieved by combining the Cas nuclease (e.g. Cas9, Cpfl and the like) with a predefined guide RNA molecule (gRNA). The gRNA is complementary to a specific DNA sequence targeted for editing in the plant genome and which guides the Cas nuclease to a specific nucleotide sequence (for example see Fig. 3). The predefined gene specific gRNA's are cloned into the same plasmid as the Cas gene and this plasmid is inserted into plant cells. Insertion of the aforementioned plasmid DNA can be done, but not limited to, using different delivery systems, biological and/or mechanical, e.g. Agrobacterium infiltration, virus based plasmids for delivery of the genome editing molecules and mechanical insertion of DNA (PEG mediated DNA transformation, biolistics, etc.).

It is further within the scope of the present invention that upon reaching the specific predetermined DNA sequence, the Cas9 nuclease cleaves both DNA strands to create double stranded breaks leaving blunt ends. This cleavage site is then repaired by the cellular non homologous end joining DNA repair mechanism resulting in insertions or deletions which eventually create a mutation at the cleavage site. For example, it is acknowledged that a deletion form of the mutation consists of at least 1 base pair deletion. As a result of this base pair deletion the gene coding sequence is disrupted and the translation of the encoded protein is compromised either by a premature stop codon or disruption of a functional or structural property of the protein. Thus DNA is cut by the Cas9 protein and re-assembled by the cell's DNA repair mechanism.

It is further within the scope that resistance to PM in Cannabis plants is produced by generating gRNA with homology to a specific site of predetermined genes in the Cannabis genome i.e. MLO genes, sub cloning this gRNA into a plasmid containing the Cas9 gene, and insertion of the plasmid into the Cannabis plant cells. In this way site specific mutations in the MLO genes are generated thus effectively creating non-active molecules, resulting in inability of powdery mildew and similar organisms of infecting the genome edited plant.

Reference is now made to Figs 1A-C schematically present Cannabis plant infected by the fungal pathogen Golovinomyces cichoracearum, causal agent of the Powdery Mildew disease. More specifically this figure shows (A) Cannabis plant leaf exhibiting PM symptoms (B) Fungal asexual spore-carrying bodies (conidia) of Golovinomyces cichoracearumon Cannabis leaf tissue, and (C) microscopic view of Golovinomyces cichoracearumspores.

Reference is now made to Fig. 2A-B schematically presenting PM resistance suggested mode of action. This figure shows (A) a WT plant cell penetrated by the PM fungus (100). More particularly, a WT plant cell 10 is infected by PM spore 20 producing germ tubes 30 and penetrated by the PM fungal appressorium 40 which then leads to haustorium 50 establishment and infection by secondary hyphae; and (B) an mlo knockout cell 15 rendering fungal spores incapable of penetrating the plant cell (200).

It is further within the scope to provide a method for identifying a Cannabis plant with resistance to powdery mildew, said method comprises steps of: (a) screening the genome of said Cannabis plant for a mutated Csmlol allele, said mutated allele comprises a genomic modification selected from an indel of 14 bp at a position corresponding to position 12 of SEQ ID NO: 882 or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO:

882, or a combination thereof; (b) optionally, regenerating plants carrying said genetic modification; and (c) optionally, screening said regenerated plants for a plant resistant to powdery mildew.

It is a further aspect of the present invention to disclose a modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein said plant comprises a targeted genome modification conferring reduced expression of at least one Cannabis MLO (CsMLO) allele as compared to a Cannabis plant lacking said targeted genome modification.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined above, wherein said targeted genome modification is in a CsMLO allele having a wild type genomic nucleotide sequence selected from the group consisting of CsMLO1 having a sequence as set forth in SEQ ID NO:1 or a functional variant thereof, CsMLO2 having a sequence as set forth in SEQ ID NO:4 or a functional variant thereof and CsMLO3 having a sequence as set forth in SEQ ID NO:7 or a functional variant thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said functional variant has at least 80% sequence identity to the corresponding CsMLO nucleotide sequence.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said plant has decreased expression levels of at least one Mlo protein, relative to a Cannabis plant lacking said at least one genome modification.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said genomic modification is introduced using mutagenesis, small interfering RNA (siRNA), microRNA (miRNA), artificial miRNA (amiRNA), DNA introgression, endonucleases or any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said genetic modification is introduced using targeted genome modification, preferably said genetic modification is introduced using an endonuclease.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above wherein said targeted genome modification is introduced using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) gene (CRISPR/Cas), Transcription activator-like effector nuclease (TALEN), Zinc Finger Nuclease (ZFN), meganuclease or any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above wherein said Cas gene is selected from the group consisting of Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, CasIO, CastlOd, Cas12, Cas13, Cas14, CasX, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpfl, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10,

Csx16, CsaX, Csx3, Cszl, Csx15, Csfl, Csf2, Csf3, Csf4, and Cu1966, bacteriophages Cas such as Cas(D (Cas-phi) and any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said plant comprises a recombinant DNA construct, said recombinant DNA construct comprising a promoter operably linked to a nucleotide sequence encoding a plant optimized Cas9 endonuclease, wherein said plant optimized Cas9 endonuclease is capable of binding to and creating a double strand break in a genomic target sequence of said plant genome.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said DNA construct further comprises sgRNA targeted to at least one CsMLO allele selected from the group consisting of CsMLO1, CsMLO2 and CsMLO3.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said sgRNA is targeted to mutate CsMLO1 gene, said sgRNA nucleotide sequence is selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said plant comprises at least one mutated CsMLO1 allele comprising a nucleotide sequence selected from the group consisting of a nucleotide sequence as set forth in SEQ ID NO:875, a nucleotide sequence as set forth in SEQ ID NO:877, a nucleotide sequence as set forth in SEQ ID NO:880, a homologue having at least 80% sequence identity to the nucleotide sequence of said at least one mutated CsMLO1 allele and a combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said mutation is a silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation or any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said genome modification is an insertion, deletion, indel or substitution.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said mutated CsMLO1 allele comprises a deletion having a nucleotide sequence as set forth in SEQ ID NO.:876, SEQ ID NO.:879 or SEQ ID NO.:881.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said mutated allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele sequence.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said wild type CsMLO1 allele comprises a nucleic acid sequence as set forth in at least one of SEQ ID NO:873, SEQ ID NO:876, SEQ ID NO:879 or SEQ ID NO:881.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above wherein said genome modification is an induced mutation in the coding region of said allele, a mutation in the regulatory region of said allele, a mutation in a gene downstream in the MLO pathogen response pathway and/or an epigenetic factor.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above wherein said genome modification is generated in planta.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above wherein said targeted genome modification is generated in plantavia introduction of a construct comprising (a) Cas DNA and sgRNA sequence selected from the group consisting of SEQ ID NO:10-SEQ ID NO:870 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and sgRNA sequence selected from the group consisting of SEQ ID NO:10-870 and any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above wherein said targeted genome modification in said CsMLO1 is generated in plantavia introduction of a construct comprising (a) Cas DNA and sgRNA sequence selected from the group consisting of SEQ ID NO:10-SEQ ID NO:286 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and sgRNA sequence selected from the group consisting of SEQ ID NO:10-286 and any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above wherein said targeted genome modification in said CsMLO2 is generated in plantavia introduction of a construct comprising (a) Cas DNA and sgRNA sequence selected from the group consisting of SEQ ID NO:287-SEQ ID NO:625 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and sgRNA sequence selected from the group consisting of SEQ ID NO:287-625 and any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said targeted genome modification in said CsMLO3 is generated in plantavia introduction of a construct comprising (a) Cas DNA and sgRNA sequence selected from the group consisting of SEQ ID NO:626-SEQ ID NO:870 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:626-870 and any combination thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said sgRNA sequence comprises a 3' Protospacer Adjacent Motif(PAM) selected from the group consisting of NGG (SpCas), NNNNGATT (NmeCas9), NNAGAAW (StCas9), NAAAAC (TdCas9), NNGRRT (SaCas9) and TBN (Cas-phi).

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said construct is introduced into the plant cells via Agrobacterium infiltration, virus based plasmids for delivery and/or expression of the genome editing molecules or mechanical insertion such as polyethylene glycol (PEG) mediated DNA transformation, electroporation or gene gun biolistics.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said PM is selected from the group consisting of Golovinomyces cichoracearum,Golovinomyces ambrosiae and a mixture thereof.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said Cannabis plant is selected from the group of species that includes, but is not limited to, Cannabis sativa (C. sativa), C. indica, C. ruderalis and any hybrid or cultivated variety of the genus Cannabis.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said Cannabis plant does not comprise a transgene.

It is a further aspect of the present invention to disclose a modified Cannabis plant, progeny plant, plant part or plant cell as defined in any of the above.

It is a further aspect of the present invention to disclose a plant part, plant cell or plant seed of a modified plant as defined in any of the above.

It is a further aspect of the present invention to disclose a tissue culture of regenerable cells, protoplasts or callus obtained from the modified Cannabis plant as defined in any of the above.

It is a further aspect of the present invention to disclose the modified Cannabis plant as defined in any of the above, wherein said plant genotype is obtainable by deposit under accession number with NCIMB Aberdeen AB21 9YA, Scotland, UK.

It is a further aspect of the present invention to disclose a method for producing a modified Cannabis plant with increased resistance to powdery mildew (PM) comprising introducing using targeted genome modification, at least one genomic modification conferring reduced expression of at least one Cannabis MLO (CsMLO) allele as compared to a Cannabis plant lacking said targeted genome modification.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said method comprises steps of introducing a targeted genome modification to at least one CsMLO allele having a wild type genomic nucleotide sequence selected from the group consisting of CsMLO1 comprising a sequence as set forth in SEQ ID NO:1 or a functional variant thereof, CsMLO2 comprising a sequence as set forth in SEQ ID NO:4 or a functional variant thereof and CsMLO3 comprising a sequence as set forth in SEQ ID NO:7 or a functional variant thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said functional variant has at least 80% sequence identity to the said CsMLO nucleotide sequence.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said method comprises steps of introducing a loss of function mutation into at least one of CsMLO1, CsMLO2 and CsMLO2 nucleic acid sequence.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said method comprises steps of introducing a deletion mutation into the first exon of CsMLO1 genomic sequence to produce a mutated CsMLO1 allele comprising a nucleotide sequence selected from the group consisting of a nucleotide sequence as set forth in SEQ ID NO:875, a nucleotide sequence as set forth in SEQ ID NO:877, a nucleotide sequence as set forth in SEQ ID NO:880, a homologue having at least 80% sequence identity to the nucleotide sequence of said at least one mutated CsMLO1 allele and a combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said modified plant has decreased levels of at least one Mlo protein as compared to wild type Cannabis plant.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said modified plant has decreased levels of at least one Mlo protein as compared to a Cannabis plant comprising a wild type CsMLO1 allele sequence comprising a nucleic acid sequence as set forth in at least one of SEQ ID NO:873, SEQ ID NO:876, SEQ ID NO:879 or SEQ ID NO:881.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said genome modification is introduced using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) gene (CRISPR/Cas), Transcription activator-like effector nuclease (TALEN), Zinc Finger Nuclease (ZFN), meganuclease or any combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said Cas gene is selected from the group consisting of Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, CaslO, CastlOd, Casl2, Cas13, Casl4, CasX, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csnl, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpfl, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Cszl, Csxl5, Csfl, Csf2, Csf3, Csf4, and Cul966, bacteriophages Cas such as CasD (Cas-phi) and any combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, comprising steps of introducing an expression vector comprising a promoter operably linked to a nucleotide sequence encoding a plant optimized Cas9 endonuclease and sgRNA targeted to at least one CsMLO allele selected from the group consisting of CsMLO1, CsMLO2 and CsMLO3.

It is a further object of the present invention to disclose the method as defined in any of the above, wherein said sgRNA nucleotide sequence targeting CsMLO1 is selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50.

It is a further aspect of the present invention to disclose the method as defined in any of the above, comprising steps of introducing and co-expressing in a Cannabis plant Cas9 and sgRNA targeted to at least one of CsMLO1, CsMLO2 and CsMLO3 genes and screening for induced targeted mutations in at least one of CsMLO1, CsMLO2 and CsMLO3 genes.

It is a further aspect of the present invention to disclose the method as defined in any of the above, comprising steps of screening for induced targeted mutations in at least one of CsMLO1, CsMLO2 and CsMLO3 genes comprising obtaining a nucleic acid sample from a transformed plant and carrying out nucleic acid amplification and optionally restriction enzyme digestion to detect a mutation in at least one of CsMLO1, CsMLO2 and CsMLO3.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said nucleic acid amplification for screening induced targeted mutations in CsMLO1 genomic sequence uses primers having nucleic acid sequence as set forth in SEQ ID NO: 871 and SEQ ID NO: 872.

It is a further aspect of the present invention to disclose the method as defined in any of the above, further comprising steps of assessing PCR fragments or amplicons amplified from the transformed plants using a gel electrophoresis based assay.

It is a further aspect of the present invention to disclose the method as defined in any of the above, further comprising steps of confirming the presence of a mutation by sequencing the at least one of CsMLO1, CsMLO2 and CsMLO3 nucleic acid fragment or amlicon.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said mutation is in the coding region of said allele, a mutation in the regulatory region of said allele, a mutation in a gene downstream in the MLO pathogen response pathway or an epigenetic factor.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said mutation is selected from the group consisting of a silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation and any combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said mutation is an insertion, deletion, indel or substitution mutation.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said mutation is a deletion in the first exon of CsMLO1, said deletion comprises nucleic acid sequence selected from the group consisting of SEQ ID NO.:876, SEQ ID NO.:879 or SEQ ID NO.:881.

It is a further aspect of the present invention to disclose the method as defined in any of the above, further comprising steps of selecting a plant resistant to powdery mildew from transformed plants comprising mutated at least one of CsMLO1, CsMLO2 and CsMLO3 nucleic acid fragment.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said selected plant is characterized by enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a CsMLO1 nucleic acid comprising a nucleic acid sequence as set forth in SEQ ID NO:873.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said genetic modification in said CsMLO1 is generated in planta via introduction of a construct comprising (a) Cas DNA and gRNA sequence selected from the group consisting of SEQ ID NO:10-SEQ ID NO:286 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:10-286 and any combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said genetic modification in said CsMLO2 is generated in planta via introduction of a construct comprising (a) Cas DNA and gRNA sequence selected from the group consisting of SEQ ID NO:287-SEQ ID NO:625 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:287-625 and any combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said genetic modification in said CsMLO3 is generated in planta via introduction of a construct comprising (a) Cas DNA and gRNA sequence selected from the group consisting of SEQ ID NO:626-SEQ ID NO:870 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:626-870 and any combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said gRNA nucleotide sequence comprises a 3' Protospacer Adjacent Motif (PAM), said PAM is selected from the group consisting of: NGG (SpCas), NNNNGATT (NmeCas9), NNAGAAW (StCas9), NAAAAC (TdCas9), NNGRRT (SaCas9) and TBN (Cas-phi).

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said construct is introduced into the plant cells using Agrobacterium infiltration, virus based plasmids for delivery of the genome editing molecules by or mechanical insertion such as polyethylene glycol (PEG) mediated DNA transformation, electroporation or gene gun biolistics.

It is a further aspect of the present invention to disclose the method as defined in any of the above, further comprising steps of regenerating a plant carrying said genomic modification.

It is a further aspect of the present invention to disclose the method as defined in any of the above, further comprising steps of screening said regenerated plants for a plant resistant to powdery mildew.

It is a further aspect of the present invention to disclose a method for conferring resistance to powdery mildew to a Cannabis plant comprising producing a plant as defined in any of the above.

It is a further aspect of the present invention to disclose a plant, plant part, plant cell, tissue culture or a seed obtained or obtainable by the method as defined in any of the above.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said PM is selected from the group consisting of Golovinomyces cichoracearum, Golovinomyces ambrosiae and a mixture thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said Cannabis plant is selected from the group of species that includes, but is not limited to, Cannabis sativa (C. sativa), C. indica, C. ruderalisand any hybrid or cultivated variety of the genus Cannabis.

It is a further aspect of the present invention to disclose a method for producing a modified Cannabis plant with increased resistance to powdery mildew compared to a Cannabis wild type plant using targeted genome modification comprising introducing at least one genetic modification conferring reduced expression of at least one Cannabis MLO (CsMLO) allele, said method comprises steps of: (a) identifying at least one Cannabis MLO (CsMLO) orthologous allele; (b) sequencing genomic DNA of said at least one identified CsMLO; (c) synthetizing at least one guide RNA (gRNA) comprising a nucleotide sequence complementary to said at least one identified CsMLO; (d) transforming Cannabis plant cells with a construct comprising (a) Cas nucleotide sequence and said gRNA, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and said gRNA; (e) screening the genome of said transformed plant cells for induced targeted mutations in at least one of said CsMLO alleles comprising obtaining a nucleic acid sample from said transformed plant and carrying out nucleic acid amplification and optionally restriction enzyme digestion to detect a mutation in said at least one of said CsMLO allele; (f) confirming the presence of said genetic mutation in the genome of said plant cells by sequencing said at least one CsMLO allele; (g) regenerating plants carrying said genetic modification; and (h) screening said regenerated plants for a plant resistant to powdery mildew.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said plant has decreased levels of at least one Mlo protein.

It is a further aspect of the present invention to disclose the method as defined in any of the above, further comprising steps of introducing into said plant sgRNA targeted to mutate CsMLO1 gene, said sgRNA nucleotide sequence is selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said plant comprises at least one mutated CsMLO1 allele comprising a nucleotide sequence selected from the group consisting of a nucleotide sequence as set forth in SEQ ID NO:875, a nucleotide sequence as set forth in SEQ ID NO:877, a nucleotide sequence as set forth in SEQ ID NO:880, a homologue having at least 80% sequence identity to the nucleotide sequence of said at least one mutatedCsMLO1 allele and a combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said mutation is a silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation or any combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said mutated CsMLO1 allele comprises a deletion having a nucleotide sequence as set forth in SEQ ID NO.:876, SEQ ID NO.:879 or SEQ ID NO.:881.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said mutated allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele sequence.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said wild type CsMLO1 allele comprises a nucleic acid sequence as set forth in at least one of SEQ ID NO:873, SEQ ID NO:876, SEQ ID NO:879 or SEQ ID NO:881.

It is a further aspect of the present invention to disclose a method of determining the presence of a mutant CsMLO1 nucleic acid in a Cannabis plant comprising assaying said Cannabis plant with primers having nucleic acid sequence as set forth in SEQ ID NO: 871 and SEQ ID NO: 872.

It is a further aspect of the present invention to disclose a method for determining the presence or absence of a mutant CsMLO1 nucleic acid or polypeptide in a Cannabis plant comprising detecting the presence or absence of a deletion of a nucleotide sequence as set forth in SEQ ID NO.:876, SEQ ID NO.:879 or SEQ ID NO.:881.

It is a further aspect of the present invention to disclose a method for identifying a Cannabis plant with resistance to powdery mildew, said method comprises steps of: (a) screening the genome of said Cannabis plant for induced targeted mutations in at least one of CsMLO1, CsMLO2 and/or CsMLO3 alleles having a wild type genomic nucleotide sequence selected from the group consisting of CsMLO1 comprising a sequence as set forth in SEQ ID NO:1 or a functional variant thereof, CsMLO2 comprising a sequence as set forth in SEQ ID NO:4 or a functional variant thereof and CsMLO3 comprising a sequence as set forth in SEQ ID NO:7 or a functional variant thereof; (b) confirming the presence of said genetic mutation in the genome of said plant cells by sequencing said at least one CsMLO allele; (c) regenerating plants carrying said genetic modification; and (d) screening said regenerated plants for a plant resistant to powdery mildew.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said screening for the presence of mutated CsMLO1 allele is carried out using a primer pair having nucleic acid sequence as set forth in SEQ ID NO: 871 and SEQ ID NO: 872.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said method comprises steps of screening for the presence of mutated CsMLO1 allele comprising a nucleic acid sequence selected from the group consisting of a nucleotide sequence as set forth in SEQ ID NO:875, a nucleotide sequence as set forth in SEQ ID NO:877, a nucleotide sequence as set forth in SEQ ID NO:880, a homologue having at least 80% sequence identity to the nucleotide sequence of said at least one mutated CsMLO1 allele and a combination thereof.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said method comprises steps of screening said Cannabis plant for the presence of a deletion in CsMLO1 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO.:876, SEQ ID NO.:879 and SEQ ID NO.:881.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:873, SEQ ID NO:876, SEQ ID NO:879 and SEQ ID NO:881 indicates that the Cannabis plant comprises wild type CsMLO1 nucleic acid, and the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:875, SEQ ID NO:877 and SEQ ID NO:880, optionally in combination with the absence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:876, SEQ ID NO:879 and SEQ ID NO:881 indicates that the Cannabis plant comprises a mutant CsMLO1 nucleic acid.

It is a further aspect of the present invention to disclose the method as defined in any of the above, wherein said Cannabis plant comprising a mutant CsMLO1 nucleic acid is characterized by enhanced resistance to powdery mildew as compared to a Cannabis plant comprising said wild type CsMLO1 nucleic acid.

It is a further aspect of the present invention to disclose an isolated nucleotide sequence of a primer or primer pair having at least 75% sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, 2, 4, 5, 7, 8 and SEQ ID NO:10-873, 875, 876, 877, 879, 880 and 881.

It is a further aspect of the present invention to disclose an isolated amino acid sequence having at least 75% sequence similarity to an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6,SEQ ID NO:9, SEQ ID NO:874, SEQ ID NO:878 and SEQ ID NO:887.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:871 and SEQ ID NO:872 as a primer or primer pair for identifying or screening for a Cannabis plant comprising within its genome mutant CsMLO1 nucleic acid and/or polypeptide.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:871 and SEQ ID NO:872 as a primer or primer pair for identifying or screening for a Cannabis plant resistance to powdery mildew.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in SEQ ID NO:873, SEQ ID NO:875, SEQ ID NO:876, SEQ ID NO:877, SEQ ID NO:879, SEQ ID NO:880 and SEQ ID NO:881 for identifying and/or screening for a Cannabis plant with comprising within its genome mutant CsMLO1 nucleic acid and/or polypeptide, wherein, the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:873, SEQ ID NO:876, SEQ ID NO:879 and SEQ ID NO:881 indicates that the Cannabis plant comprises wild type CsMLO1 nucleic acid, and the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:875, SEQ ID NO:877 and SEQ ID NO:880, optionally in combination with the absence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:876, SEQ ID NO:879 and SEQ ID NO:881 indicates that the Cannabis plant comprises a mutant CsMLO1 nucleic acid.

It is a further aspect of the present invention to disclose the use as defined in any of the above, wherein said Cannabis plant comprising a mutant CsMLO1 nucleic acid is characterized by enhanced resistance to powdery mildew as compared to a Cannabis plant comprising said wild type CsMLO1 nucleic acid.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:10-870 and any combination thereof for targeted genome modification of at least one Cannabis MLO (CsMLO) allele.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:10-286 and any combination thereof for targeted genome modification of Cannabis CsMLO1 allele.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 and any combination thereof for targeted genome modification of Cannabis CsMLO1 allele.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:287-625 and any combination thereof for targeted genome modification of Cannabis CsMLO2 allele.

It is a further aspect of the present invention to disclose use of a nucleotide sequence as set forth in at least one of SEQ ID NO:626-870 and any combination thereof for targeted genome modification of Cannabis CsMLO3.

It is a further aspect of the present invention to disclose a detection kit for determining the presence or absence of a mutant CsMLO1 nucleic acid nucleic acid or polypeptide in a Cannabis plant.comprising a primer selected from SEQ ID NO:871 and SEQ ID NO:872.

It is a further aspect of the present invention to disclose the detection kit as defined in any of the above, wherein said kit further comprising primers or nucleic acid fragments for detection of a nucleic acid sequence selected from the group consisting of SEQ ID NO:873, SEQ ID NO:875, SEQ ID NO:876, SEQ ID NO:877, SEQ ID NO:879, SEQ ID NO:880 and SEQ ID NO:881.

It is a further aspect of the present invention to disclose the detection kit as defined in any of the above, wherein said kit is useful for identifying a Cannabis plant resistant to powdery mildew.

In order to understand the invention and to see how it may be implemented in practice, a plurality of preferred embodiments will now be described, by way of non-limiting example only, with reference to the following examples.

EXAMPLE 1

Exemplified method for production of powdery mildew resistant Cannabis plants by genome editing

Production of powdery mildew resistant Cannabis lines may be achieved by at least one of the following breeding/cultivation schemes:

Scheme 1:

• line stabilization by self pollination • Generation of F6 parental lines • Genome editing of parental lines • Crossing edited parental lines to generate an F1 hybrid PM resistant plant

Scheme 2:

• Identifying genes of interest • Designing gRNA • Transformation of plants with Cas9+gRNA constructs • Screening and identifying editing events • Genome editing of parental lines

It is noted that line stabilization may be performed by the following:

• Induction of male flowering on female (XX) plants • Self pollination

According to some embodiments of the present invention, line stabilization requires 6 self-crossing (6 generations) and done through a single seed descent (SSD) approach.

Fl hybrid seed production: Novel hybrids are produced by crosses between different Cannabis strains.

According to a further aspect of the current invention, shortening line stabilization is performed by Doubled Haploids (DH). More specifically, the CRISPR-Cas9 system is transformed into microspores to achieve DH homozygous parental lines. A doubled haploid (DH) is a genotype formed when haploid cells undergo chromosome doubling. Artificial production of doubled haploids is important in plant breeding. It is herein acknowledged that conventional inbreeding procedures take six generations to achieve approximately complete homozygosity, whereas doubled haploidy achieves it in one generation.

It is within the scope of the current invention that genetic markers specific for Cannabis are developed and provided by the current invention:

• Sex markers- molecular markers are used for identification and selection of female vs male plants in the herein disclosed breeding program • Genotyping markers- germplasm used in the current invention is genotyped using molecular markers, in order to allow a more efficient breeding process and identification of the MLO editing event.

It is further within the scope of the current invention that allele and genetic variation is analysed for the Cannabis strains used.

Reference is now made to optional stages that have been used for the production of powdery mildew resistant Cannabis plants by genome editing:

Stage 1: Identifying Cannabissativa (C. sativa) MLO orthologues, Three MLO orthologues have herein been identified in C. sativa, namely CsMLO1, CsMLO2 and CsMLO3. These homologous genes have been sequenced and mapped. CsMLO1 has been found to be located on chromosome between position 58544241bp and position 58551241bp and has a genomic sequence as set forth in SEQ ID NO:1. The CsMLO1 gene has a coding sequence as set forth in SEQ ID NO:2 and it encodes an amino acid sequence as set forth in SEQ ID NO:3.

CsMLO2 has been found to be located on chromosome 3 between position 92616000bp and position 92629000bp and has a genomic sequence as set forth in SEQ ID NO:4. The CsMLO2 gene has a coding sequence as set forth in SEQ ID NO:5 and it encodes an amino acid sequence as set forth in SEQ ID NO:6.

CsMLO3 has been found to be located on Chromosome 5 between position 23410000bp and position 23420000bp and has a genomic sequence as set forth in SEQ ID NO:7. The CsMLO3 gene has a coding sequence as set forth in SEQ ID NO:8 and it encodes an amino acid sequence as set forth in SEQ ID NO:9.

Stage 2: Designing and synthesizing gRNA molecules corresponding to the sequence targeted for editing, i.e. sequences of each of the genes CsMLO1, CsMLO2 and CsMLO3. It is noted that the editing event is preferably targeted to a unique restriction site sequence to allow easier screening for plants carrying an editing event within their genome. According to some aspects of the invention, the nucleotide sequence of the gRNAs should be completely compatible with the genomic sequence of the target gene. Therefore, for example, suitable gRNA molecules should be constructed for different MLO homologues of different Cannabis strains.

Reference is now made to Tables 1, 2 and 3 presenting gRNA molecules constructed for silencing CsMLO1, CsMLO2 and CsMLO3, respectively. In Tables 1, 2 and 3 the term 'PAM' refers to protospacer adjacent motif, which is a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease in the CRISPR bacterial adaptive immune system. The CsMLO genomic DNA sense strand is marked as "1",and the antisense strand is marked as "-1".

Table 1: CsMLO1 targeted gRNA sequences

Position Strand Sequence PAM SEQ ID on SEQ NO ID NO:1 30 1 GTGAGTGAATGAGAGCAAGA AGG 10 59 -1 ATTCCGATTTCGAATTCAGA TGG 11 67 1 AATCCATCTGAATTCGAAAT CGG 12 76 1 GAATTCGAAATCGGAATGAG TGG 13 79 1 TTCGAAATCGGAATGAGTGG CGG 14 82 1 GAAATCGGAATGAGTGGCGG TGG 15 88 1 GGAATGAGTGGCGGTGGAGA AGG 16 99 1 CGGTGGAGAAGGTGAGTCCT TGG 17 105 -1 CCATGTGGGAGTATACTCCA AGG 18 116 1 CCTTGGAGTATACTCCCACA TGG 19 119 -1 ACGACGGCGACGATCCATGT GGG 20 120 -1 GACGACGGCGACGATCCATG TGG 21 135 -1 GACGATGACAGAGCAGACGA CGG 22

159 -1 ACGCTCCGCGGCGAGAGAAA TGG 23 165 1 CGTCGCCATTTCTCTCGCCG CGG 24 171 -1 ATAGTGGAGAAGACGCTCCG CGG 25 187 1 GAGCGTCTTCTCCACTATCT CGG 26 187 -1 TCAAAACCTGACCGAGATAG TGG 27 192 1 TCTTCTCCACTATCTCGGTC AGG 28 220 -1 AGGCCTCGTATAGAGGCTTC TGG 29 227 -1 TTCTGCAAGGCCTCGTATAG AGG 30 228 1 GAACCAGAAGCCTCTATACG AGG 31 240 -1 CTCCTCCTTGATCTTCTGCA AGG 32 246 1 CGAGGCCTTGCAGAAGATCA AGG 33 249 1 GGCCTTGCAGAAGATCAAGG AGG 34 264 1 CAAGGAGGAGTTGATGCTTT TGG 35 265 1 AAGGAGGAGTTGATGCTTTT GGG 36 292 -1 TTGTGTTCTGCGAAACAGTG AGG 37 332 -1 AGATTGTCGACCAAAGAAGC AGG 38 333 1 GTTTTGCGTACCTGCTTCTT TGG 39 355 -1 GATGAGGGCGCTTACAAGGG AGG 40 358 -1 CCTGATGAGGGCGCTTACAA GGG 41 359 -1 TCCTGATGAGGGCGCTTACA AGG 42 369 1 CCCTTGTAAGCGCCCTCATC AGG 43 370 -1 AATCATTAGCTTCCTGATGA GGG 44 371 -1 GAATCATTAGCTTCCTGATG AGG 45 405 -1 AGAGCCGGAGATGTGATGAG AGG 46 412 1 TCAACCTCTCATCACATCTC CGG 47 420 -1 AAGAAGGCGTCTGAAAGAGC CGG 48 436 -1 CAGTGGAAGTTTCTTCAAGA AGG 49 453 -1 GCAATAACCCAAATGAGCAG TGG 50 456 1 AGAAACTTCCACTGCTCATT TGG 51 457 1 GAAACTTCCACTGCTCATTT GGG 52 474 1 TTTGGGTTATTGCGCTCATA AGG 53 501 -1 ACAACAACAACTAAAGATAT GGG 54 502 -1 AACAACAACAACTAAAGATA TGG 55 521 1 TTAGTTGTTGTTGTTTTTTT AGG 56 522 1 TAGTTGTTGTTGTTTTTTTA GGG 57 523 1 AGTTGTTGTTGTTTTTTTAG GGG 58 570 1 TATAAATATACTTTCCCAAA AGG 59 571 1 ATAAATATACTTTCCCAAAA GGG 60 573 -1 TAAAGCGAATAGTCCCTTTT GGG 61 574 -1 TTAAAGCGAATAGTCCCTTT TGG 62 657 -1 ATGCTTCAACGGAATAAAAG GGG 63 658 -1 AATGCTTCAACGGAATAAAA GGG 64 659 -1 CAATGCTTCAACGGAATAAA AGG 65 668 -1 CAAATGGTGCAATGCTTCAA CGG 66 684 -1 CGAAGATAAAGATATGCAAA TGG 67

708 -1 AAGTGACATGGACAATGGCT AGG 68 713 -1 ACAGAAAGTGACATGGACAA TGG 69 720 -1 TGAGAACACAGAAAGTGACA TGG 70 744 1 TGTGTTCTCACTGTTGTGTT TGG 71 747 1 GTTCTCACTGTTGTGTTTGG AGG 72 755 1 TGTTGTGTTTGGAGGTGTAA AGG 73 779 -1 GAGAGAGAAGCATATGAATT TGG 74 860 1 TACACAACTAGATACGTCAA TGG 75 869 1 AGATACGTCAATGGAAACGT TGG 76 870 1 GATACGTCAATGGAAACGTT GGG 77 873 1 ACGTCAATGGAAACGTTGGG AGG 78 910 1 GAGAGTTATGACACTGAACA AGG 79 937 -1 TTCTATAATATTGTCAAAAG TGG 80 978 -1 TAAGCGATTCATATGTTAGA AGG 81 1017 1 TGTTCTTAAGTCTAAGAAAA AGG 82 1039 -1 CCTTAATGAACGCGTGTTGA TGG 83 1050 1 CCATCAACACGCGTTCATTA AGG 84 1062 1 GTTCATTAAGGACCACTTTT TGG 85 1063 1 TTCATTAAGGACCACTTTTT GGG 86 1063 -1 CTTTACCAAAACCCAAAAAG TGG 87 1069 1 AAGGACCACTTTTTGGGTTT TGG 88 1090 1 GGTAAAGACTCAGCTCTACT AGG 89 1094 1 AAGACTCAGCTCTACTAGGC TGG 90 1098 1 CTCAGCTCTACTAGGCTGGC TGG 91 1140 -1 ATAATCCTAATTCAGAACTT TGG 92 1146 1 AGTATCCAAAGTTCTGAATT AGG 93 1159 1 CTGAATTAGGATTATTCTTA TGG 94 1174 -1 ATATCAAGAGAATAAGAAAA CGG 95 1214 -1 AACGTTCTCAAAATAGAAAG TGG 96 1267 -1 CTCCAAAGGCTCAGTATCAA TGG 97 1276 1 CTCCATTGATACTGAGCCTT TGG 98 1281 -1 GTGATGGAGAAAATCTCCAA AGG 99 1297 -1 ATGTCCTAGTTTTCATGTGA TGG 100 1304 1 TTCTCCATCACATGAAAACT AGG 101 1327 1 ACATTTTTGTGCACATGTTA AGG 102 1349 1 GAGCTAGCTAACATTAACAT TGG 103 1356 1 CTAACATTAACATTGGAAAC AGG 104 1379 -1 GGGGAAAAAGAATCAAATCA TGG 105 1398 -1 AAAAGCATGCTGTTCACAAG GGG 106 1399 -1 CAAAAGCATGCTGTTCACAA GGG 107 1400 -1 ACAAAAGCATGCTGTTCACA AGG 108 1446 -1 CATGGTCGCATAATCTGATT TGG 109 1460 1 AATCAGATTATGCGACCATG CGG 110 1464 -1 CATGATGAATCCTAACCGCA TGG 111 1465 1 GATTATGCGACCATGCGGTT AGG 112

1476 1 CATGCGGTTAGGATTCATCA TGG 113 1520 1 TTACTTATAAATTACTAGAA TGG 114 1563 1 CTTTTTTTCTTTTCACTAAA TGG 115 1603 1 TTGTATTCTAGACTCACTGC AGG 116 1604 1 TGTATTCTAGACTCACTGCA GGG 117 1605 1 GTATTCTAGACTCACTGCAG GGG 118 1674 1 GATGATTTCAAGAAAGTTGT TGG 119 1675 1 ATGATTTCAAGAAAGTTGTT GGG 120 1681 1 TCAAGAAAGTTGTTGGGATA AGG 121 1691 1 TGTTGGGATAAGGTAACCCT TGG 122 1696 -1 GAAAATAGACTGTCAACCAA GGG 123 1697 -1 AGAAAATAGACTGTCAACCA AGG 124 1777 1 TTCTTTTAAGTCTACTGTAT CGG 125 1792 -1 AAAAGCTAAAAGGTCAATCT AGG 126 1802 -1 ACTGCAGCCAAAAAGCTAAA AGG 127 1806 1 AGATTGACCTTTTAGCTTTT TGG 128 1816 1 TTTAGCTTTTTGGCTGCAGT TGG 129 1825 1 TTGGCTGCAGTTGGTACCTT TGG 130 1826 1 TGGCTGCAGTTGGTACCTTT GGG 131 1830 -1 AGATGACCACAAAAACCCAA AGG 132 1835 1 TTGGTACCTTTGGGTTTTTG TGG 133 1863 1 TTCTTGTTGCTGAATGTTAA TGG 134 1910 -1 ATCACTTAGATCTTGAGTTA TGG 135 1926 1 ACTCAAGATCTAAGTGATAT TGG 136 1958 -1 CAAAGAACCAGACTGATTAC GGG 137 1959 -1 ACAAAGAACCAGACTGATTA CGG 138 1962 1 GCAGAATCCCGTAATCAGTC TGG 139 1999 1 CTTCAAGTGTGTCATCTCTT TGG 140 2033 -1 GCTTATTTGAAACTATAATT TGG 141 2101 -1 GTGGAGGCAGAGTAAGGAAT TGG 142 2107 -1 AGAAAAGTGGAGGCAGAGTA AGG 143 2117 -1 CTCCAACCATAGAAAAGTGG AGG 144 2120 -1 TTTCTCCAACCATAGAAAAG TGG 145 2122 1 ACTCTGCCTCCACTTTTCTA TGG 146 2126 1 TGCCTCCACTTTTCTATGGT TGG 147 2148 1 GAGAAAATTATACTCCAAGT TGG 148 2151 -1 TCCAATTCCTTACACCAACT TGG 149 2155 1 TTATACTCCAAGTTGGTGTA AGG 150 2161 1 TCCAAGTTGGTGTAAGGAAT TGG 151 2203 1 TCACTAGAATGCAATCAACA AGG 152 2204 1 CACTAGAATGCAATCAACAA GGG 153 2244 -1 AATTTTTTTAATCAGAATTC TGG 154 2293 -1 TAAAAGTAAACTAAATTTCT TGG 155 2347 -1 ATGTAAATTATGTTCTATAT AGG 156 2380 -1 GATCCAATTGAATTATCTTA AGG 157

2388 1 ACACCTTAAGATAATTCAAT TGG 158 2406 1 ATTGGATCTTACTCCTTGTT TGG 159 2408 -1 GCCTCATTGTAGTCCAAACA AGG 160 2418 1 TCCTTGTTTGGACTACAATG AGG 161 2453 -1 ATCTTGGTTTGAGTATTGAG AGG 162 2469 -1 ATATAAATAATGAATGATCT TGG 163 2497 -1 CAAAGAAGTTTAATACACAC TGG 164 2516 1 TATTAAACTTCTTTGTTGTA TGG 165 2559 1 TTTTGTCAATGTTTTGTGAT TGG 166 2597 1 TAATAATGTGTTATATTTGC AGG 167 2601 1 AATGTGTTATATTTGCAGGC TGG 168 2616 1 CAGGCTGGCACACATaTTTC TGG 169 2640 -1 CTCAATAAACTCACAAAGAA AGG 170 2709 1 CATGTTTCATTGTTCTTGCA TGG 171 2750 1 CATTTTAAGTATCATACTGA TGG 172 2774 1 GAAAGAGATAAAATACAGAG AGG 173 2775 1 AAAGAGATAAAATACAGAGA GGG 174 2783 1 AAAATACAGAGAGGGAGAAT CGG 175 2784 1 AAATACAGAGAGGGAGAATC GGG 176 2817 1 TTTAACACAATTTTGTAAAT AGG 177 2824 1 CAATTTTGTAAATAGGCAAA TGG 178 2837 1 AGGCAAATGGACAGCTAAGA AGG 179 2852 -1 TGTTCAATTAATTCTAAATT TGG 180 2875 1 TTAATTGAACAACATGACCT AGG 181 2881 -1 AAATTGCACAATATTTACCT AGG 182 2950 1 TAAATGTAGAGTCATGAGTC AGG 183 2951 1 AAATGTAGAGTCATGAGTCA GGG 184 2973 1 GTAGAAATTTGCACCTAGAC AGG 185 2975 -1 CACCTTAAAACCACCTGTCT AGG 186 2976 1 GAAATTTGCACCTAGACAGG TGG 187 2984 1 CACCTAGACAGGTGGTTTTA AGG 188 2987 1 CTAGACAGGTGGTTTTAAGG TGG 189 3011 1 ACTTCTCATCTCCAAGTCTT AGG 190 3011 -1 CATACATATCACCTAAGACT TGG 191 3046 -1 ATGTATATCACAACAGCAAA AGG 192 3083 -1 TTAAAAGAAAAAACAACAAG TGG 193 3114 1 TAAATAGCTTCTACTTGCCG TGG 194 3115 1 AAATAGCTTCTACTTGCCGT GGG 195 3120 -1 ATGCTCCAGTTTAGTGCCCA CGG 196 3126 1 ACTTGCCGTGGGCACTAAAC TGG 197 3147 1 GGAGCATGTCATTACTCAGT TGG 198 3184 1 GAGAAACATGTAGCAATAGA AGG 199 3212 -1 AACCAAAAGTGATCATCTGA TGG 200 3221 1 AGCCATCAGATGATCACTTT TGG 201 3242 -1 ATCAGGAAGAGGACAATCTG GGG 202

3243 -1 AATCAGGAAGAGGACAATCT GGG 203 3244 -1 GAATCAGGAAGAGGACAATC TGG 204 3253 -1 TGATGAAATGAATCAGGAAG AGG 205 3259 -1 AAAGGATGATGAAATGAATC AGG 206 3277 -1 TCTCAAATGAATTTTGGAAA AGG 207 3283 -1 ACGCAATCTCAAATGAATTT TGG 208 3305 1 TTGAGATTGCGTTTTTCTTC TGG 209 3312 1 TGCGTTTTTCTTCTGGATAT TGG 210 3320 1 TCTTCTGGATATTGGTAAGC TGG 211 3343 -1 TGGTAGAAGTAGAAGCAGAG TGG 212 3363 -1 AATAACAATTTGTTCTTTTT TGG 213 3411 1 ATCTTCTTTTCTGTGTATCT AGG 214 3441 1 TTCATTTAACTCCTGTATAA TGG 215 3441 -1 ACGAACGTGTCCCATTATAC AGG 216 3442 1 TCATTTAACTCCTGTATAAT GGG 217 3472 -1 TTTACCCAATGACAAGTCTT GGG 218 3473 -1 TTTTACCCAATGACAAGTCT TGG 219 3478 1 ATTGTCCCAAGACTTGTCAT TGG 220 3479 1 TTGTCCCAAGACTTGTCATT GGG 221 3541 -1 TAAAATAAAAGTTTCGTACT TGG 222 3570 -1 GAACACCCTAAAGCACAACA TGG 223 3575 1 TTTTTACCATGTTGTGCTTT AGG 224 3576 1 TTTTACCATGTTGTGCTTTA GGG 225 3588 1 GTGCTTTAGGGTGTTCATTC AGG 226 3622 -1 GTGTGACAATGGCATAGAGC GGG 227 3623 -1 TGTGTGACAATGGCATAGAG CGG 228 3633 -1 TCAACGCACCTGTGTGACAA TGG 229 3636 1 GCTCTATGCCATTGTCACAC AGG 230 3681 1 ATAATTTAATAAGTTCTAAA AGG 231 3689 1 ATAAGTTCTAAAAGGAAAGT AGG 232 3720 -1 CATTCCACAAGATTTTATTA TGG 233 3727 1 CTGACCATAATAAAATCTTG TGG 234 3743 1 CTTGTGGAATGATTTGAAGA TGG 235 3744 1 TTGTGGAATGATTTGAAGAT GGG 236 3773 1 TTACAAGAAAGCCATATTTG AGG 237 3773 -1 TTGCATGCGCTCCTCAAATA TGG 238 3789 1 TTTGAGGAGCGCATGCAAGT AGG 239 3802 1 TGCAAGTAGGAATTGTTAAT TGG 240 3803 1 GCAAGTAGGAATTGTTAATT GGG 241 3812 1 AATTGTTAATTGGGCTCAGA AGG 242 3827 1 TCAGAAGGTCAAGAAAAAGA AGG 243 3828 1 CAGAAGGTCAAGAAAAAGAA GGG 244 3849 1 GGATTTAAAGCAGCCCTCAT TGG 245 3851 -1 GCCAGCACCGGAACCAATGA GGG 246 3852 -1 AGCCAGCACCGGAACCAATG AGG 247

3855 1 AAAGCAGCCCTCATTGGTTC CGG 248 3861 1 GCCCTCATTGGTTCCGGTGC TGG 249 3863 -1 GCCTGAGCCTGAGCCAGCAC CGG 250 3867 1 ATTGGTTCCGGTGCTGGCTC AGG 251 3873 1 TCCGGTGCTGGCTCAGGCTC AGG 252 3879 1 GCTGGCTCAGGCTCAGGCTC AGG 253 3884 1 CTCAGGCTCAGGCTCAGGCT CGG 254 3885 1 TCAGGCTCAGGCTCAGGCTC GGG 255 3891 1 TCAGGCTCAGGCTCGGGATC AGG 256 3903 1 TCGGGATCAGGCTCTACTCC TGG 257 3910 -1 GTATCAGAAATTGGTTGACC AGG 258 3919 -1 GCAGAACCAGTATCAGAAAT TGG 259 3924 1 GGTCAACCAATTTCTGATAC TGG 260 3938 1 TGATACTGGTTCTGCATCTG TGG 261 3939 1 GATACTGGTTCTGCATCTGT GGG 262 3950 1 TGCATCTGTGGGAATTCAGC TGG 263 3951 1 GCATCTGTGGGAATTCAGCT GGG 264 3973 -1 TGCTCTGGCTTTGATGCTTT GGG 265 3974 -1 CTGCTCTGGCTTTGATGCTT TGG 266 3988 -1 TTAGAGTCATCACTCTGCTC TGG 267 4058 1 GAAGACATAAGTCTACCCTT AGG 268 4062 -1 CTAGTAGTAGTATTACCTAA GGG 269 4063 -1 ACTAGTAGTAGTATTACCTA AGG 270 4088 -1 ATCCCAGCACAGCTGGAAAG TGG 271 4095 -1 ATTTCTAATCCCAGCACAGC TGG 272 4096 1 TTGCCACTTTCCAGCTGTGC TGG 273 4097 1 TGCCACTTTCCAGCTGTGCT GGG 274 4132 1 AATTCTTCTGTCATATATTA TGG 275 4138 1 TCTGTCATATATTATGGCTG TGG 276 4141 1 GTCATATATTATGGCTGTGG TGG 277 4142 1 TCATATATTATGGCTGTGGT GGG 278 4160 -1 GTCTTGTCCATAAAAGACTT AGG 279 4164 1 GACTGTACCTAAGTCTTTTA TGG 280 4188 -1 TTATATAATATATTGATCAA AGG 281 4267 1 CTTCTTTCTTCTTATTATCA TGG 282 4280 1 ATTATCATGGTACATCCTTT TGG 283 4284 -1 TTCACTATTCAGTTACCAAA AGG 284 4312 1 AGTGAATACGTGTAGTCTCA TGG 285 4313 1 GTGAATACGTGTAGTCTCAT GGG 286

Table 2: CsMLO2 targeted gRNA sequences

Position Strand Sequence PAM SEQ ID on SEQ NO ID NO:4

1977 -1 GTATGAATATGAAATTAAGT TGG 287 2044 -1 AGAGAGAGAGAGACAGAGAG TGG 288

2117 -1 TTGAAATTGGGATGGAGATG TGG 289

2125 -1 ATTCTGTTTTGAAATTGGGA TGG 290

2129 -1 GTAAATTCTGTTTTGAAATT GGG 291

2130 -1 TGTAAATTCTGTTTTGAAAT TGG 292

2153 -1 GTTAGAATGAAAAGTTTGAT GGG 293

2154 -1 AGTTAGAATGAAAAGTTTGA TGG 294

2211 1 TATAATCAATTATTCCCAAG TGG 295

2214 -1 TAAATATAAATAGGCCACTT GGG 296

2215 -1 ATAAATATAAATAGGCCACT TGG 297 2223 -1 TAGTGATCATAAATATAAAT AGG 298

2278 1 AAAATTAAATTAAAAGAAGA TGG 299

2281 1 ATTAAATTAAAAGAAGATGG CGG 300

2284 1 AAATTAAAAGAAGATGGCGG TGG 301

2291 1 AAGAAGATGGCGGTGGCTAG CGG 302 2294 1 AAGATGGCGGTGGCTAGCGG AGG 303 2322 1 CTTTAGAACAAACACCAACA TGG 304

2323 1 TTTAGAACAAACACCAACAT GGG 305

2325 -1 ACTACGGCCACAGCCCATGT TGG 306 2329 1 ACAAACACCAACATGGGCTG TGG 307 2341 -1 TACCAAAACAAGACAAACTA CGG 308

2350 1 GGCCGTAGTTTGTCTTGTTT TGG 309

2371 -1 GATTATGTGCTCAATAATAA TGG 310

2393 1 GAGCACATAATCCATCTCAT TGG 311

2393 -1 GGTATACCTTGCCAATGAGA TGG 312

2398 1 CATAATCCATCTCATTGGCA AGG 313

2414 -1 TGAGATTAATATATATAATT GGG 314

2415 -1 GTGAGATTAATATATATAAT TGG 315

2473 1 CATTTAATTATTTAAATTAA TGG 316

2474 1 ATTTAATTATTTAAATTAAT GGG 317

2495 1 GGTATTTTTTTTTTTTTTAG TGG 318 2535 1 ACGAGCTCTTTATGAATCGT TGG 319

2551 1 TCGTTGGAAAAGATCAAATC AGG 320

2576 -1 AAAATGGGTATTCATTAATT GGG 321

2577 -1 AAAAATGGGTATTCATTAAT TGG 322

2591 -1 TTAAAAAAAAAAACAAAAAT GGG 323

2656 1 TTTGATAGAGCTTATGTTAT TGG 324

2657 1 TTGATAGAGCTTATGTTATT GGG 325

2658 1 TGATAGAGCTTATGTTATTG GGG 326

2680 1 GTTCATATCGTTGTTACTAA CGG 327 2683 1 CATATCGTTGTTACTAACGG TGG 328

2684 1 ATATCGTTGTTACTAACGGT GGG 329

2703 -1 GATATACAAATATTTGAGAT CGG 330

2726 1 ATTTGTATATCTGAGAAAAT TGG 331

2729 1 TGTATATCTGAGAAAATTGG AGG 332

2730 1 GTATATCTGAGAAAATTGGA GGG 333

2736 1 CTGAGAAAATTGGAGGGACA TGG 334

2751 -1 TCTTCTTGTTCTTTATTACA AGG 335

2777 1 CAAGAAGAGAAATTGAATAA AGG 336

2778 1 AAGAAGAGAAATTGAATAAA GGG 337 2779 1 AGAAGAGAAATTGAATAAAG GGG 338

2817 1 TCGAACATGAAAGTAACAGT CGG 339

2827 1 AAGTAACAGTCGGAGATTGC TGG 340

2839 -1 ACCGTCGCCGGACTCTAAAA AGG 341 2843 1 TTGCTGGCCTTTTTAGAGTC CGG 342

2849 1 GCCTTTTTAGAGTCCGGCGA CGG 343

2851 -1 GACACTAGCAGCACCGTCGC CGG 344 2865 1 GCGACGGTGCTGCTAGTGTC CGG 345 2873 -1 CGGCCGCCGCCAAAATTCGC CGG 346 2875 1 TGCTAGTGTCCGGCGAATTT TGG 347 2878 1 TAGTGTCCGGCGAATTTTGG CGG 348

2881 1 TGTCCGGCGAATTTTGGCGG CGG 349 2885 1 CGGCGAATTTTGGCGGCGGC CGG 350 2886 1 GGCGAATTTTGGCGGCGGCC GGG 351 2893 -1 TTCAGCACACTTATCAGTCC CGG 352

2908 1 GACTGATAAGTGTGCTGAAA AGG 353

2978 1 GTCTTTCTTATCCTTTTATT TGG 354 2978 -1 GACGAATATGTCCAAATAAA AGG 355

3000 -1 CTCCTATAATATTATATGTT TGG 356

3009 1 GTCCAAACATATAATATTAT AGG 357 3051 -1 AAATATATAAATTTAAAGGT TGG 358

3055 -1 AACTAAATATATAAATTTAA AGG 359

4125 1 AAATTATATACATATATGAA TGG 360

4168 1 ATATATATAATTATAATTTC AGG 361

4169 1 TATATATAATTATAATTTCA GGG 362

4187 -1 ATACCATCCGCCGAAACAAA TGG 363

4188 1 AGGGCAAGTTCCATTTGTTT CGG 364

4191 1 GCAAGTTCCATTTGTTTCGG CGG 365

4195 1 GTTCCATTTGTTTCGGCGGA TGG 366

4230 1 GCATATTTTTATCTTTGTGT TGG 367 4249 -1 TCATGATGCAGTAGAGAACA TGG 368

4272 1 CTGCATCATGACTATGTTTT TGG 369

4273 1 TGCATCATGACTATGTTTTT GGG 370 4284 1 TATGTTTTTGGGCAGACTTA AGG 371 4404 -1 AATTTATATATAATTATTTA GGG 372

4405 -1 CAATTTATATATAATTATTT AGG 373

4428 1 TATATAAATTGATTCCCAGA TGG 374

4429 1 ATATAAATTGATTCCCAGAT GGG 375

4431 -1 ATGCTTCCAACTTCCCATCT GGG 376 4432 -1 AATGCTTCCAACTTCCCATC TGG 377 4436 1 TTGATTCCCAGATGGGAAGT TGG 378 4445 1 AGATGGGAAGTTGGAAGCAT TGG 379 4446 1 GATGGGAAGTTGGAAGCATT GGG 380

4452 1 AAGTTGGAAGCATTGGGAAA AGG 381

4476 -1 ACCATGTGAGAATTGATATT CGG 382

4486 1 GCCGAATATCAATTCTCACA TGG 383

4548 1 CTTAATTTTAATTTTTCTAT AGG 384

4551 1 AATTTTAATTTTTCTATAGG TGG 385

4649 -1 CTATATGACATATTTGATGG TGG 386

4652 -1 TAACTATATGACATATTTGA TGG 387

4742 1 AATTATAAGAGCATCTTTAT TGG 388

4749 1 AGAGCATCTTTATTGGACAC CGG 389

4757 -1 TAGAAAGTGTTAAATATCAC CGG 390

4844 -1 TATTGGTATAATTAAGTATC AGG 391

4861 -1 CTTACCAATTATATTATTAT TGG 392

4868 1 TATACCAATAATAATATAAT TGG 393

4903 1 ATTTATAAGAAGTATATATA TGG 394

4904 1 TTTATAAGAAGTATATATAT GGG 395

4923 1 TGGGAGTTAGAATTAAGTAA AGG 396

4997 -1 CTCGCAAATCTGAATCTTTC TGG 397 5009 1 CAGAAAGATTCAGATTTGCG AGG 398

5010 1 AGAAAGATTCAGATTTGCGA GGG 399

5023 1 TTTGCGAGGGACACTTCTTT TGG 400

5045 1 GAAGAAGACATTTAAGTTTC TGG 401

5058 -1 CCATATTAGGAAAGGGTGTT TGG 402

5065 -1 TTACTATCCATATTAGGAAA GGG 403

5066 -1 CTTACTATCCATATTAGGAA AGG 404

5069 1 CCAAACACCCTTTCCTAATA TGG 405

5071 -1 GGGATCTTACTATCCATATT AGG 406

5091 -1 AAGTAAAAAGTGGGTAAAAA GGG 407 5092 -1 AAAGTAAAAAGTGGGTAAAA AGG 408

5100 -1 AATATAAAAAAGTAAAAAGT GGG 409

5101 -1 GAATATAAAAAAGTAAAAAG TGG 410

5149 -1 ATATAAGTGCATGGATATAG TGG 411 5158 -1 TATTAATAGATATAAGTGCA TGG 412

5233 -1 CATATTTATATGCATGTGAA AGG 413

5253 1 TGCATATAAATATGTTTGCA TGG 414

5269 1 TGCATGGTTTTTATACATCG TGG 415

7159 1 TATATATATAATATTTTTTT TGG 416

7213 -1 TTAATTAATAATTAAAGAGC AGG 417

7238 1 ATTAATTAATTATTTTTCGC AGG 418

7282 -1 AAAGTTAAATAATCAACTTT AGG 419

7302 1 GATTATTTAACTTTGAGACA TGG 420

7313 1 TTTGAGACATGGATTTATAA TGG 421

7373 1 ATTATAGCTGTAGAGATATT TGG 422

7387 -1 TAAGTATTATTAAAAATACA AGG 423

8017 -1 GAATGAGAATAGGAATAGAA TGG 424

8027 -1 ATAGGAATGGGAATGAGAAT AGG 425

8039 -1 ATAGGAATAGAAATAGGAAT GGG 426

8040 -1 TATAGGAATAGAAATAGGAA TGG 427 8045 -1 GAAAATATAGGAATAGAAAT AGG 428

8057 -1 GTTGAGAGGAATGAAAATAT AGG 429

8071 -1 CACAGAGGCGTTTGGTTGAG AGG 430

8079 -1 AATAGGCCCACAGAGGCGTT TGG 431

8083 1 CTCTCAACCAAACGCCTCTG TGG 432

8084 1 TCTCAACCAAACGCCTCTGT GGG 433

8086 -1 ACAAGATAATAGGCCCACAG AGG 434

8096 -1 TTAATACATAACAAGATAAT AGG 435

8150 1 ATCAATAACTAAATTAATTG AGG 436

8177 1 TTATAACAATTAATAATTTC AGG 437 8186 1 TTAATAATTTCAGGCACATT TGG 438

8198 -1 AAATTTTTGATGGCTTTGAG GGG 439

8199 -1 CAAATTTTTGATGGCTTTGA GGG 440

8200 -1 TCAAATTTTTGATGGCTTTG AGG 441

8208 -1 TTTGAAAGTCAAATTTTTGA TGG 442

8255 1 ATCTCTAGAAGAAGATTTCA AGG 443

8265 1 GAAGATTTCAAGGTCGTTGT AGG 444

8272 1 TCAAGGTCGTTGTAGGAATC AGG 445

8345 -1 ATTAAAATAAGTCATCATTT GGG 446 8346 -1 AATTAAAATAAGTCATCATT TGG 447 8399 1 TAATAATTATTATTTTGTTT TGG 448

8427 1 TCAATCTCAGTCCTCCTATT TGG 449

8427 -1 ACAGCGAAGAACCAAATAGG AGG 450

8430 -1 ACCACAGCGAAGAACCAAAT AGG 451

8440 1 TCCTATTTGGTTCTTCGCTG TGG 452

8465 1 TTCTTACTCTTCAATACCCA TGG 453

8470 -1 AATAATAAAATGCTCACCAT GGG 454

8471 -1 TAATAATAAAATGCTCACCA TGG 455

8500 -1 GGATGCATTGAAATAATTAA TGG 456

8521 -1 AATCTAAACTGTGATAATTA GGG 457

8522 -1 AAATCTAAACTGTGATAATT AGG 458

8566 -1 TTGACATATATGCACACGTT TGG 459

8605 1 TATATTTTTGTTTTTATTAT TGG 460 8618 -1 AAATGTAAACAAATTCATTA TGG 461

8631 1 ATAATGAATTTGTTTACATT TGG 462

8636 1 GAATTTGTTTACATTTGGAC AGG 463

8640 1 TTGTTTACATTTGGACAGGC TGG 464

8655 1 CAGGCTGGTATTCTTATCTT TGG 465 8670 -1 CTTACAATTAGAGGAATAAA AGG 466

8679 -1 ATATTAGTACTTACAATTAG AGG 467 8820 -1 GATTGTTTGAATTTTATTTT TGG 468

8907 -1 GTTTACAGTAAAACTTTAAA AGG 469

8932 -1 AATTAGCCCAATTTTTTTCA CGG 470 8936 1 TAAACTACCGTGAAAAAAAT TGG 471 8937 1 AAACTACCGTGAAAAAAATT GGG 472

9001 -1 CTCTTTTATTTTTTAAGAAG AGG 473

9053 1 TATTATAAATAAATTATGTT AGG 474

9065 1 ATTATGTTAGGTGATCCTAT TGG 475

9068 1 ATGTTAGGTGATCCTATTGG TGG 476

9069 1 TGTTAGGTGATCCTATTGGT GGG 477 9069 -1 GTAATTTCGTCCCCACCAAT AGG 478

9070 1 GTTAGGTGATCCTATTGGTG GGG 479 9101 1 ACAAGTGATTATAACAAAGA TGG 480

9102 1 CAAGTGATTATAACAAAGAT GGG 481 9103 1 AAGTGATTATAACAAAGATG GGG 482

9123 1 GGGCTAAGAATTCAAGAAAG AGG 483

9138 1 GAAAGAGGAGAAGTTGTAAA AGG 484

9149 1 AGTTGTAAAAGGAGTGCCTG TGG 485

9154 -1 TCGTCCCCAGGTTGGACCAC AGG 486 9159 1 GGAGTGCCTGTGGTCCAACC TGG 487 9160 1 GAGTGCCTGTGGTCCAACCT GGG 488 9161 1 AGTGCCTGTGGTCCAACCTG GGG 489 9162 -1 AGAAAAGGTCGTCCCCAGGT TGG 490

9166 -1 AACCAGAAAAGGTCGTCCCC AGG 491

9175 1 AACCTGGGGACGACCTTTTC TGG 492

9177 -1 GTGGGCGGTTGAACCAGAAA AGG 493

9192 -1 GGTAGAGAATAAGGCGTGGG CGG 494 9195 -1 TAAGGTAGAGAATAAGGCGT GGG 495

9196 -1 ATAAGGTAGAGAATAAGGCG TGG 496

9201 -1 AGTTAATAAGGTAGAGAATA AGG 497 9213 -1 GGAAGAGGACGAAGTTAATA AGG 498

9227 1 TATTAACTTCGTCCTCTTCC AGG 499

9228 -1 ATTGATTATGTACCTGGAAG AGG 500

9234 -1 ATTTTGATTGATTATGTACC TGG 501

9254 1 TAATCAATCAAAATCAGCCT TGG 502

9260 -1 GGTGCATTATAGAATTTCCA AGG 503

9281 -1 TCAATGTATTCATTTTAAGG GGG 504

9282 -1 ATCAATGTATTCATTTTAAG GGG 505

9283 -1 CATCAATGTATTCATTTTAA GGG 506

9284 -1 GCATCAATGTATTCATTTTA AGG 507 9308 -1 TTGAGTGCTAAAACAAGTAA GGG 508

9309 -1 TTTGAGTGCTAAAACAAGTA AGG 509

9350 1 TTTAGTCAAATTTTTTCTCA TGG 510

10632 -1 TCCATGCAAAGAACGCAAGC TGG 511

10642 1 TCCAGCTTGCGTTCTTTGCA TGG 512

10648 1 TTGCGTTCTTTGCATGGACT TGG 513

10649 1 TGCGTTCTTTGCATGGACTT GGG 514

10753 1 TTAATTTTTCAGTATGAATT TGG 515

10785 1 TTGCTTTCATGAACATGTTG AGG 516

10791 1 TCATGAACATGTTGAGGATG TGG 517 10809 1 TGTGGTTATCAGAATCACCA TGG 518

10810 1 GTGGTTATCAGAATCACCAT GGG 519

10811 1 TGGTTATCAGAATCACCATG GGG 520

10815 -1 ATATCTGTATACAGACCCCA TGG 521

10922 -1 AAATAAAAATTAAATATTAA TGG 522

10958 1 GTAAAAATTTCTAACACCGT TGG 523

10963 -1 CCCTGATGATCATGATCCAA CGG 524

10973 1 ACCGTTGGATCATGATCATC AGG 525

10974 1 CCGTTGGATCATGATCATCA GGG 526

10993 -1 TGACGTAGCTGCACAGAATC TGG 527

11016 -1 AACAAGGGCGTAGAGAGGGA GGG 528

11017 -1 TAACAAGGGCGTAGAGAGGG AGG 529

11020 -1 GTGTAACAAGGGCGTAGAGA GGG 530

11021 -1 TGTGTAACAAGGGCGTAGAG AGG 531

11031 -1 TGTAATTACTTGTGTAACAA GGG 532

11032 -1 GTGTAATTACTTGTGTAACA AGG 533

11159 -1 AGATTTTATATATTTAATTA GGG 534

11160 -1 TAGATTTTATATATTTAATT AGG 535

11524 -1 CGGACTATATTTTAATTAAA AGG 536

11544 -1 TAATTAAATAAAATTCTAAA CGG 537 11580 1 TAAAAAATATTGTCATAGTT TGG 538

11581 1 AAAAAATATTGTCATAGTTT GGG 539

11782 1 TATATATATGACACAACAGA TGG 540

11783 1 ATATATATGACACAACAGAT GGG 541

11800 -1 GTTGAATATAGTTGGTTTCA TGG 542

11808 -1 ACTTTGTCGTTGAATATAGT TGG 543

11824 1 TATATTCAACGACAAAGTAG CGG 544

11827 1 ATTCAACGACAAAGTAGCGG AGG 545

11839 -1 TGAGTGGTGCCAGTTGCGGA GGG 546

11840 -1 CTGAGTGGTGCCAGTTGCGG AGG 547 11841 1 TAGCGGAGGCCCTCCGCAAC TGG 548

11843 -1 GGGCTGAGTGGTGCCAGTTG CGG 549 11855 -1 TGATGTGCTTTCGGGCTGAG TGG 550

11863 -1 TTGGTGTTTGATGTGCTTTC GGG 551 11864 -1 TTTGGTGTTTGATGTGCTTT CGG 552

11881 1 GCACATCAAACACCAAAACA AGG 553

11882 -1 CTGACCCCGCCGCCTTGTTT TGG 554

11884 1 CATCAAACACCAAAACAAGG CGG 555

11887 1 CAAACACCAAAACAAGGCGG CGG 556

11888 1 AAACACCAAAACAAGGCGGC GGG 557 11889 1 AACACCAAAACAAGGCGGCG GGG 558

11910 -1 GTCGTCGGCCGGCTTGACAG CGG 559 11913 1 CAGTGACGCCGCTGTCAAGC CGG 560 11921 -1 GATGTGTGGGTGTCGTCGGC CGG 561 11925 -1 ATGTGATGTGTGGGTGTCGT CGG 562

11934 -1 ACCGGGGACATGTGATGTGT GGG 563

11935 -1 GACCGGGGACATGTGATGTG TGG 564

11944 1 ACCCACACATCACATGTCCC CGG 565

11950 -1 GTGGCGCAAGAGGTGGACCG GGG 566 11951 -1 AGTGGCGCAAGAGGTGGACC GGG 567 11952 -1 TAGTGGCGCAAGAGGTGGAC CGG 568

11957 -1 TGCGGTAGTGGCGCAAGAGG TGG 569 11960 -1 CACTGCGGTAGTGGCGCAAG AGG 570 11969 -1 CTGCTGCCTCACTGCGGTAG TGG 571 11974 1 CTTGCGCCACTACCGCAGTG AGG 572

11975 -1 GGCTGTCTGCTGCCTCACTG CGG 573 11996 -1 AGCGCCTTGGGGAGTTTTGG AGG 574

11999 -1 TTGAGCGCCTTGGGGAGTTT TGG 575

12003 1 ACAGCCTCCAAAACTCCCCA AGG 576

12007 -1 ATCAAAGTTTGAGCGCCTTG GGG 577 12008 -1 CATCAAAGTTTGAGCGCCTT GGG 578 12009 -1 CCATCAAAGTTTGAGCGCCT TGG 579 12020 1 CCAAGGCGCTCAAACTTTGA TGG 580

12033 1 ACTTTGATGGCGCCACTGAA CGG 581

12034 -1 ATCTGTCTCCCACCGTTCAG TGG 582

12036 1 TTGATGGCGCCACTGAACGG TGG 583

12037 1 TGATGGCGCCACTGAACGGT GGG 584

12059 -1 TGGTGGTGGTGAGATGGAGA TGG 585

12065 -1 CGGCCGTGGTGGTGGTGAGA TGG 586 12073 1 TCTCCATCTCACCACCACCA CGG 587 12073 -1 TCGCGAAGCGGCCGTGGTGG TGG 588 12076 -1 CGGTCGCGAAGCGGCCGTGG TGG 589 12079 -1 CCTCGGTCGCGAAGCGGCCG TGG 590 12085 -1 AGGAACCCTCGGTCGCGAAG CGG 591 12090 1 CCACGGCCGCTTCGCGACCG AGG 592 12091 1 CACGGCCGCTTCGCGACCGA GGG 593 12096 -1 ATGATGAGAGGAGGAACCCT CGG 594

12105 -1 ATTATTACTATGATGAGAGG AGG 595

12108 -1 ATTATTATTACTATGATGAG AGG 596

12150 1 TAAAAATCAGCAAATTGAAT TGG 597

12151 1 AAAAATCAGCAAATTGAATT GGG 598

12162 1 AATTGAATTGGGACAAATAA TGG 599

12181 1 ATGGAACAACATCATCTTCA TGG 600

12188 1 AACATCATCTTCATGGAGAT CGG 601

12204 -1 GGTTTGAGGAGGAAGCTCAT TGG 602

12215 -1 CTTAATGTAGTGGTTTGAGG AGG 603

12218 -1 TTTCTTAATGTAGTGGTTTG AGG 604

12225 -1 AGCTTGATTTCTTAATGTAG TGG 605

12267 1 TGATCAATCAGCAGCAGCAC AGG 606

12272 1 AATCAGCAGCAGCACAGGTG AGG 607 12284 -1 TTAATTTCATGGTGGGGCGG CGG 608

12287 -1 ATATTAATTTCATGGTGGGG CGG 609

12290 -1 CCAATATTAATTTCATGGTG GGG 610

12291 -1 TCCAATATTAATTTCATGGT GGG 611

12292 -1 GTCCAATATTAATTTCATGG TGG 612

12295 -1 TGTGTCCAATATTAATTTCA TGG 613

12301 1 CCCCACCATGAAATTAATAT TGG 614

12326 1 ACAGAGATTTCTCTTTTGAA CGG 615

12350 -1 CTCTCTCGTCATCAAACGCT GGG 616

12351 -1 TCTCTCTCGTCATCAAACGC TGG 617 12376 1 CGAGAGAGAATTCCGTTATT TGG 618

12377 -1 TTAACATTATAACCAAATAA CGG 619

12392 1 TATTTGGTTATAATGTTAAT CGG 620

12396 1 TGGTTATAATGTTAATCGGA CGG 621 12411 1 TCGGACGGTTCTCATTGTCT CGG 622

12423 -1 TCTAGCTCGTTGATCATCAG AGG 623

12499 -1 ATAATTAAACCGCTCATTAT TGG 624

12501 1 TAAGCAGCTCCAATAATGAG CGG 625

Table 3: CsMLO3 targeted gRNA sequences

Position Strand Sequence PAM SEQ ID on SEQ NO ID NO:7

777 1 TGAAACTCAAACTAAAATCA AGG 626

801 -1 TCTAACAGTTGGTATCAGAG CGG 627 812 -1 ATATATAAATGTCTAACAGT TGG 628

860 1 ATATGTTTAAGTATTAACTG CGG 629

894 1 TATATACACTATATAACTTA AGG 630

915 -1 GCTCAAGAATCAATGGCTGG AGG 631

918 -1 GAAGCTCAAGAATCAATGGC TGG 632

922 -1 GTTTGAAGCTCAAGAATCAA TGG 633

944 -1 TTGCAGATCAAAGCTTATGT GGG 634

945 -1 CTTGCAGATCAAAGCTTATG TGG 635 957 1 CACATAAGCTTTGATCTGCA AGG 636

958 1 ACATAAGCTTTGATCTGCAA GGG 637 965 1 CTTTGATCTGCAAGGGAAAC TGG 638

974 1 GCAAGGGAAACTGGTTGATG TGG 639

975 1 CAAGGGAAACTGGTTGATGT GGG 640

982 1 AACTGGTTGATGTGGGTAAT CGG 641

983 1 ACTGGTTGATGTGGGTAATC GGG 642

998 -1 TAAAGAGAGTTGAGAGAGCG AGG 643

1014 1 CTCTCTCAACTCTCTTTAGA TGG 644

1044 1 TGTTATGAACAGAATGAGTG AGG 645

1051 1 AACAGAATGAGTGAGGAGCT CGG 646

1052 1 ACAGAATGAGTGAGGAGCTC GGG 647 1053 1 CAGAATGAGTGAGGAGCTCG GGG 648

1066 -1 CACCTATAAATATAGGGTCT CGG 649

1072 -1 GTATCTCACCTATAAATATA GGG 650

1073 -1 AGTATCTCACCTATAAATAT AGG 651

1075 1 GACCGAGACCCTATATTTAT AGG 652

1096 -1 TAATGTGGCACAGATACTGA TGG 653

1111 -1 AAATATTCTGACAATTAATG TGG 654

1138 1 AATATTTTGACAATTAATTC AGG 655

1151 1 TTAATTCAGGAAATCAAATC AGG 656

1183 -1 ATTATGTAATATTCTATATA TGG 657 4585 1 GTTCTCACTATCAGTTATTA TGG 658

4595 1 TCAGTTATTATGGTTATTTA TGG 659

4615 1 TGGTTATTTATCTTTTTTAG TGG 660

4634 -1 CCTGAAGGGCTTTTTGTGTT TGG 661

4645 1 CCAAACACAAAAAGCCCTTC AGG 662

4648 -1 CTTCTCAAGCGCTTCCTGAA GGG 663

4649 -1 TCTTCTCAAGCGCTTCCTGA AGG 664

4670 1 GCGCTTGAGAAGATTAAATT AGG 665

4736 1 TTATTAGTATTTTTTTTTTT TGG 666

4751 1 TTTTTTGGTCTAATTTTAAT TGG 667 4752 1 TTTTTGGTCTAATTTTAATT GGG 668

4802 1 TGTTGCAGAGCTTATGCTAT TGG 669

4803 1 GTTGCAGAGCTTATGCTATT GGG 670 4842 -1 ATATGTCAGCAATGTAATCT TGG 671 4870 -1 CAAGTGTTTGCTGCACTTTT TGG 672

4882 1 CAAAAAGTGCAGCAAACACT TGG 673

4897 -1 TCTTCATTTTGGTATGGGCA AGG 674

4902 -1 TTTTCTCTTCATTTTGGTAT GGG 675

4903 -1 TTTTTCTCTTCATTTTGGTA TGG 676

4908 -1 TAGCCTTTTTCTCTTCATTT TGG 677

4916 1 ATACCAAAATGAAGAGAAAA AGG 678 4922 1 AAATGAAGAGAAAAAGGCTA AGG 679 4945 -1 TAATCAATTGTTTTTGATTT TGG 680

5012 1 TGTAATTATGTCTTAATGAT AGG 681

5033 1 GGACGTATACTAAAAGTGTG TGG 682

5078 1 AATGAGTTCTGAATTTTTGA AGG 683

5098 1 AGGACTTTTTGAATATTGTA TGG 684

5139 1 TAATATAAAATTAATATATA TGG 685 5181 1 TGATTTGTGTGTTTTGTGTG AGG 686

5187 1 GTGTGTTTTGTGTGAGGTGC AGG 687 5188 1 TGTGTTTTGTGTGAGGTGCA GGG 688

5214 1 AGTTCTTTAGTGTCTAAATA TGG 689

5215 1 GTTCTTTAGTGTCTAAATAT GGG 690

5232 -1 CAAATATGAAGATATGAAGC TGG 691

5249 1 TCATATCTTCATATTTGTCT TGG 692

5268 -1 TAGTAATGCAATATATAATA TGG 693

5285 1 TATATATTGCATTACTACCT TGG 694

5291 -1 TTTGGTTCTGCCAATAGCCA AGG 695

5292 1 TGCATTACTACCTTGGCTAT TGG 696

5309 -1 AACTTAAAAACTACTCACTT TGG 697 5361 1 CATATTCTATAAAATTAATA TGG 698 5401 1 TTGAATTGCAGATGAGAAAA TGG 699 5410 1 AGATGAGAAAATGGAAAGTT TGG 700 5411 1 GATGAGAAAATGGAAAGTTT GGG 701 5414 1 GAGAAAATGGAAAGTTTGGG AGG 702

5450 1 ATTGAGTACATATATAGTAA CGG 703

5537 1 TTGTATAATTAATTATTTTT TGG 704

5563 1 CACTACAACTTATCTAACTC AGG 705

6711 -1 ATCTTTACATTCTTACTTTT TGG 706

6785 1 TATATAAATATTCAATCAAA TGG 707 6789 1 TAAATATTCAATCAAATGGT TGG 708 6811 -1 CTTGTAAATCTAAATCTCTC AGG 709 6837 1 TTTACAAGAGACACATCATT TGG 710 6859 1 GAAGAAGACATTTGAACATT TGG 711 6873 -1 TCCAAAGTGAAATTGGTGAT TGG 712

6880 -1 CTTACAATCCAAAGTGAAAT TGG 713

6883 1 GCCAATCACCAATTTCACTT TGG 714

6927 -1 TTGTTTTCTTCTCTATAATA AGG 715

6973 1 TCAAAAGTTTTTTATTATAT AGG 716

7030 1 TTCTTGTTTATCAAATGATC AGG 717

7055 1 TGCTTTTTCAGACAATTCTT CGG 718

7056 1 GCTTTTTCAGACAATTCTTC GGG 719

7069 1 ATTCTTCGGGTCAGTCACTA AGG 720

7089 1 AGGTTGATTACATGACACTG AGG 721

7094 1 GATTACATGACACTGAGGCA TGG 722

7105 1 ACTGAGGCATGGATTTGTAA TGG 723

7126 1 GGTATGTTGCACAATGATCT TGG 724

7137 1 CAATGATCTTGGCCTGAAAA TGG 725

7138 -1 TGTAATTTGAAGCCATTTTC AGG 726

7203 1 AGCTATGCTTTTCCCATTTC AGG 727

7204 -1 GAGCCAAATGTGCCTGAAAT GGG 728

7205 -1 GGAGCCAAATGTGCCTGAAA TGG 729

7212 1 TTTCCCATTTCAGGCACATT TGG 730

7226 -1 TCAAATCTTGTTTCACTTTC TGG 731

7272 1 CATCAGCAAATCACTTGATC AGG 732

7291 1 CAGGATTTTGTAGTAATTGT TGG 733

7292 1 AGGATTTTGTAGTAATTGTT GGG 734

7323 -1 ATATTATAAGCTGATTTCAA AGG 735

7419 -1 CGGCAACGAACCAAATTACT GGG 736

7420 1 ATATATGCAGCCCAGTAATT TGG 737

7420 -1 ACGGCAACGAACCAAATTAC TGG 738

7439 -1 GTTGGACAGTAGAAACAATA CGG 739

7457 -1 CAATAACTTACCATATGTGT TGG 740

7458 1 TTTCTACTGTCCAACACATA TGG 741

7519 -1 CAACATTTCAGTCACTGAAA TGG 742

7549 1 GTTGTTCTTTTTTAATTAAC AGG 743

7568 1 CAGGAATATACTCTTATTTG TGG 744

7583 -1 CTTACAATCAAAGGTAGAAA TGG 745

7592 -1 TGTGTTGTACTTACAATCAA AGG 746

7660 -1 TTCCACACATTAGCAAATGT GGG 747

7661 -1 TTTCCACACATTAGCAAATG TGG 748

7669 1 GTCCCACATTTGCTAATGTG TGG 749

7699 1 TTGTGATATATAAGATGAAT AGG 750

7715 1 GAATAGGCTACTCCTTTTAT AGG 751

7716 1 AATAGGCTACTCCTTTTATA GGG 752

7716 -1 CCATTTGAAAACCCTATAAA AGG 753

7727 1 CCTTTTATAGGGTTTTCAAA TGG 754

7741 -1 ATTTAGGAATAAGATGAATG GGG 755

7742 -1 AATTTAGGAATAAGATGAAT GGG 756

7743 -1 GAATTTAGGAATAAGATGAA TGG 757

7757 -1 GACATACCATGTTAGAATTT AGG 758

7762 1 CTTATTCCTAAATTCTAACA TGG 759

7788 -1 AAAAACCCAACACTGGAAAG TGG 760

7793 1 TGTGTGCCACTTTCCAGTGT TGG 761

7794 1 GTGTGCCACTTTCCAGTGTT GGG 762

7795 -1 ACAGGTCAAAAACCCAACAC TGG 763

7813 -1 AAATTTGTAGATTTTGAAAC AGG 764

7849 -1 CCAAATATCGGAAAATTTGT GGG 765

7850 -1 GCCAAATATCGGAAAATTTG TGG 766

7860 1 CCCACAAATTTTCCGATATT TGG 767

7861 -1 AATCTCACAAGGCCAAATAT CGG 768

7872 -1 ACATTTGAAAGAATCTCACA AGG 769

7892 1 ATTCTTTCAAATGTCACGTT CGG 770

7900 1 AAATGTCACGTTCGGTCCTG TGG 771

7905 -1 AACGACCTTTCAGAGACCAC AGG 772

7911 1 TCGGTCCTGTGGTCTCTGAA AGG 773

7935 -1 CGTTTGGGCCTGAAAAGTGT GGG 774

7936 -1 ACGTTTGGGCCTGAAAAGTG TGG 775

7938 1 TCGTTATACCCACACTTTTC AGG 776

7950 -1 TTAATACACTCCTCACGTTT GGG 777

7951 1 ACTTTTCAGGCCCAAACGTG AGG 778

7951 -1 CTTAATACACTCCTCACGTT TGG 779

7991 1 AGTCTCACATTGCTAATGTA TGG 780 8020 1 ATTGTGATATATAAAATGAA TGG 781 8021 1 TTGTGATATATAAAATGAAT GGG 782

8038 -1 TAAAACTAATTGGCTGTGGG AGG 783

8041 -1 TCTTAAAACTAATTGGCTGT GGG 784

8042 -1 ATCTTAAAACTAATTGGCTG TGG 785

8048 -1 GGTTTTATCTTAAAACTAAT TGG 786

8069 -1 ATTTAGGGATAAGATGAATG GGG 787

8070 -1 AATTTAGGGATAAGATGAAT GGG 788

8071 -1 GAATTTAGGGATAAGATGAA TGG 789 8084 -1 ATTAAGCATGTTAGAATTTA GGG 790 8085 -1 GATTAAGCATGTTAGAATTT AGG 791 8144 1 CAAATTGCAGATAATATTAC TGG 792

8147 1 ATTGCAGATAATATTACTGG TGG 793

8148 1 TTGCAGATAATATTACTGGT GGG 794

8180 1 TCAAGTAATCATAACAAAGA TGG 795

8181 1 CAAGTAATCATAACAAAGAT GGG 796

8202 1 GGATTAAGCATTCAAGAGAG AGG 797 8210 1 CATTCAAGAGAGAGGAGATG TGG 798 8217 1 GAGAGAGGAGATGTGGTAAA AGG 799 8228 1 TGTGGTAAAAGGTGCACCAT TGG 800

8233 -1 TCATCTCCTGGTTGAACCAA TGG 801

8238 1 GGTGCACCATTGGTTCAACC AGG 802

8245 -1 AACCAGAAGAGGTCATCTCC TGG 803

8254 1 AACCAGGAGATGACCTCTTC TGG 804

8256 -1 TAGGCCGTCCGAACCAGAAG AGG 805

8259 1 GGAGATGACCTCTTCTGGTT CGG 806

8263 1 ATGACCTCTTCTGGTTCGGA CGG 807 8275 -1 ATGAGAAAGAGCATTAATTT AGG 808

8301 -1 TAAGTACCTGAAAGAGAACA AGG 809

8306 1 CATTCACCTTGTTCTCTTTC AGG 810

8413 1 AAAATGATATCTTTTCTGCT TGG 811

8429 1 TGCTTGGTACTAATTAATGC TGG 812

8487 -1 TACTGTACTCCATGCAAAAA AGG 813

8489 1 TTCAACTTGCCTTTTTTGCA TGG 814

8531 -1 TGCCTTGAAACCAAAAATCA AGG 815

8532 1 ATTTGACTTTCCTTGATTTT TGG 816

8540 1 TTCCTTGATTTTTGGTTTCA AGG 817 8559 1 AAGGCAATAAAATTATTACA TGG 818

8624 -1 TTCGTGGAAGCAAGTGTTCA AGG 819

8640 -1 TGATATCTTCAATTTTTTCG TGG 820

8669 1 TATCATCATAAGAATTTCAA TGG 821

8670 1 ATCATCATAAGAATTTCAAT GGG 822

8671 1 TCATCATAAGAATTTCAATG GGG 823

8805 1 TTCTCTTTTTCTTTCTTACT AGG 824

8819 -1 AACTGCATAGAACTTGTATG AGG 825 8853 -1 TGTGTGACAAGAGCATATAG AGG 826

8866 1 TCTATATGCTCTTGTCACAC AGG 827 8893 -1 GATGATAATGATGATTTAGA AGG 828

8954 1 ATTTGATCATATATTACAGA TGG 829

8955 1 TTTGATCATATATTACAGAT GGG 830

8956 1 TTGATCATATATTACAGATG GGG 831

8980 -1 ACTCTGTCATTGAAAATTAC TGG 832

9013 1 TAGCAACAGCATTAAAGAAC TGG 833

9027 -1 TGTTCTTGGTTTTGGCTGAA TGG 834

9035 -1 GTGTTTTTTGTTCTTGGTTT TGG 835

9041 -1 TCGGTTGTGTTTTTTGTTCT TGG 836

9059 1 CAAAAAACACAACCGAAATT CGG 837 9060 -1 GCGAGTTTGTCTCCGAATTT CGG 838

9082 -1 GTTGCAGGCCTACTTGAGAA TGG 839

9085 1 CAAACTCGCCATTCTCAAGT AGG 840

9097 -1 ATGCCATATGTTGGAGTTGC AGG 841

9105 1 AGGCCTGCAACTCCAACATA TGG 842

9106 -1 ACTGGAGACATGCCATATGT TGG 843

9124 -1 TAATTTTGCAGCAGATGAAC TGG 844

9156 1 TACAGAAGCACAGCAACTGA TGG 845

9165 1 ACAGCAACTGATGGATACTA TGG 846

9175 1 ATGGATACTATGGTTCTCCG AGG 847 9181 -1 TTTTCGACATTAGACATCCT CGG 848

9213 1 AACGATTACTATGAGCCTGA AGG 849

9214 1 ACGATTACTATGAGCCTGAA GGG 850

9217 -1 TTGGGAGATGGTGTCCCTTC AGG 851

9229 -1 GATGGTCCATTGTTGGGAGA TGG 852

9234 1 GGGACACCATCTCCCAACAA TGG 853

9235 -1 GCTGCAGATGGTCCATTGTT GGG 854

9236 -1 TGCTGCAGATGGTCCATTGT TGG 855

9247 -1 TGTATTTCACTTGCTGCAGA TGG 856

9284 1 GAATAACTATGAAGTTGAGA AGG 857 9296 1 AGTTGAGAAGGATATAAGTG AGG 858

9300 1 GAGAAGGATATAAGTGAGGA AGG 859

9311 1 AAGTGAGGAAGGACAGCCAA TGG 860 9316 -1 GAGCTTGGTTCCTGAACCAT TGG 861

9317 1 GGAAGGACAGCCAATGGTTC AGG 862

9331 -1 TTTTGCTGTGAGGAGGAGCT TGG 863

9338 -1 GACCTCATTTTGCTGTGAGG AGG 864

9341 -1 CTTGACCTCATTTTGCTGTG AGG 865

9347 1 CTCCTCCTCACAGCAAAATG AGG 866

9368 -1 CCTAAATGAGAAGTGAGATA AGG 867 9379 1 CCTTATCTCACTTCTCATTT AGG 868

9450 1 CTTTATTTCTTATTATCTTT TGG 869

9498 1 AATATGTATAAGCTTGAATT TGG 870

Reference is made to Table 4 summarizing sequences relating to WT CsMLO within the scope of the current invention.

Table 4: WT CsMLO sequence table

Sequence type CsMLO1 CsMLO2 CsMLO3 characterization

Genomic SEQ ID NO:1 SEQ ID NO:4 SEQ ID NO:7 sequence

Coding sequence SEQ ID NO:2 SEQ ID NO:5 SEQ ID NO:8 (CDS)

Amino acid SEQ ID NO:3 SEQ ID NO:6 SEQ ID NO:9 sequence

gRNA sequence SEQ ID NO:10- SEQ ID NO:287- SEQ ID NO:626 SEQ ID NO:286 SEQ ID NO:625 SEQ ID NO:870 (Table 1) (Table 2) (Table 3)

The above gRNA molecules have been cloned into suitable vectors and their sequence has been verified. In addition different Cas9 versions have been analyzed for optimal compatibility between the Cas9 protein activity and the gRNA molecule in the Cannabis plant.

Stage 3: Transforming Cannabis plants using Agrobacterium or biolistics (gene gun) methods. For Agrobacterium and bioloistics a DNA plasmid carrying (Cas9 + gene specific gRNA) can be used. A vector containing a selection marker, Cas9 gene and relevant gene specific gRNA's is constructed. For biolistics, Ribonucleoprotein (RNP) complexes carrying (Cas9 protein + gene specific gRNA) are used. RNP complexes are created by mixing the Cas9 protein with relevant gene specific gRNA's.

According to some embodiments of the present invention, transformation of various Cannabis tissues was performed using particle bombardment of:

• DNA vectors

• Ribonucleoprotein complex (RNP's)

According to further embodiments of the present invention, transformation of various Cannabis tissues was performed using Agrobacterium (Agrobacteriumtumefaciens) by:

• Regeneration-based transformation • Floral-dip transformation • Seedling transformation

Transformation efficiency by A. tumefaciens has been compared to the bombardment method by transient GUS transformation experiment. After transformation, GUS staining of the transformants has been performed.

Reference is now made to Fig. 4A-D photographically presenting GUS staining after transient transformation of the following Cannabis tissues (A) axillary buds (B) leaf (C) calli, and (D) cotyledons.

Fig. 4 demonstrates that various Cannabis tissues have been successfully transiently transformed using biolistics system. Transformation has been performed into calli, leaves, axillary buds and cotyledons of Cannabis.

According to further embodiments of the present invention, additional transformation tools were used in Cannabis, including, but not limited to:

• Protoplast PEG transformation • Extend RNP use • Directed editing screening using fluorescent tags • Electroporation

Stage 4: Regeneration in tissue-culture. When transforming DNA constructs into the plant, antibiotics is used for selection of positive transformed plants. An improved regeneration protocol was herein established for the Cannabis plant.

Reference is now made to Fig. 5 presenting regeneration of Cannabis tissue. In this figure, arrows indicate new meristem emergence.

Stage 5: Selection of positive transformants. Once regenerated plants appear in tissue culture, DNA is extracted from leaf sample of the transformed plant and PCR is performed using primers flanking the edited region. PCR products are then digested with enzymes recognizing the restriction site near the original gRNA sequence. If editing event occurred, the restriction site will be disrupted and the PCR product will not be cleaved. No editing event will result in a cleaved PCR product.

Reference is now made to Fig. 6 showing PCR detection of Cas9 DNA in shoots of transformed Cannabis plants. DNA extracted from shoots of plants transformed with Cas9 using biolistics. This figure shows that three weeks post transformation, Cas9 DNA was detected in shoots of transformed plants.

Screening for CRISPR/Cas9 gene editing events has been performed by at least one of the following analysis methods:

• Restriction Fragment Length Polymorphism (RFLP) • Next Generation Sequencing (NGS) • PCR fragment analysis • Fluorescent-tag based screening • High resolution melting curve analysis (HRMA)

Reference is now made to Fig. 7 presenting results of in vitro analysis of CRISPR/Cas9 cleavage activity. Fig. 7A schematically shows the genomic area targeted for editing (PAM is marked in red) and amplified by the reverse and forward designed primers Fig. 7B photographically presents a gel showing successful digestion of the resulted PCR amplicon containing the gene specific gRNA sequence, by RNP complex containing Cas9. The analysis included the following steps:

1) Amplicon was isolated from two exemplified Cannabis strains by primers flanking the sequence of the gene of interest targeted by the predesigned sgRNA. 2) RNP complex was incubated with the isolated amplicon. • 3) The reaction mix was then loaded on agarose gel to evaluate Cas9 cleavage activity at the target site.

Stage 6: Selection of transformed Cannabis plants presenting resistance to PM by establishing a protocol adapted for Cannabis. It is within the scope that different gRNA promoters were tested in order to maximize editing efficiency.

EXAMPLE 2

Identifying powdery mildew (PM) pathogen specific for Cannabis

Powdery Mildew is one of the most destructive fungal pathogens infecting Cannabis. It is an obligate biotroph that can vascularize into the plant tissue and remain invisible to a grower. Under ideal conditions, powdery mildew has a 4-7 days post inoculation (dpi) window where it remains invisible as it builds a network internally in the plant. It is herein acknowledged that the powdery mildew vascularized network in Cannabis is detectable with a PCR DNA based test prior to conidiospore generation. At later stages, powdery mildew infection and conidiospore generation results in rapid spreading of the fungus to other plants. This tends to emerge and sporulate within 2 weeks into flowering thus destroying very mature crops with severe economic consequences. DNA based tools could facilitate early detection and rapid removal of infected plant materials or screening of incoming clones.

To date, there are no fungal disease resistant Cannabis varieties on the market. Golovinomyces cichoracearumis known for causing PM on several Cucurbits and on Cannabis (P6pin et al., 2018). In order to identify the specific fungi type affecting Cannabis, a molecular analysis has been performed. Internal Transcribed Spacer (ITS) DNA of PM samples obtained from Cannabis strains growing in our greenhouse has been isolated and sequenced. The term Internal transcribed spacer (ITS) as used hereinafter refers to the spacer DNA region situated between the small-subunit ribosomal RNA (rRNA) and large-subunit rRNA genes in the chromosome or the corresponding transcribed region in the polycistronic rRNA precursor transcript. It is herein acknowledged that the internal transcribed spacer (ITS) region is considered to have the highest probability of successful identification for the broadest range of fungi, with the most clearly defined barcode gap between inter- and intraspecific variation. Thus ITS is proposed for adoption as the primary fungal barcode marker, namely as potential DNA marker or finger print for fungi (Schoch C.L. et al, PNAS, 2012 109 (16) 6241-6246). The results of the molecular analysis of PM isolated from Cannabis revealed that Golovinomyces ambrosiae or Golovinomyces cichoracearumare the cause of the disease.

A further achievement of the present invention is the establishment of an inoculation assay and index for Cannabis, or in other words establishment of bio-assay for powdery mildew inoculation in Cannabis. Such an assay establishment may include:

• Development of susceptibility index

• Designing a protocol by testing different inoculation approaches at several plant developmental stages

EXAMPLE 3

Production of genome-edited Cannabis MLO (CsMLO) genes

Three single guide RNAs (sgRNA) targeting the first exon (exon 1) of the CsMLO1 gene were designed and synthesized. These sgRNAs include sgRNA having nucleotide sequence as set forth in SEQ ID NO:17 (first guide), SEQ ID NO:43 (second guide) and SEQ ID NO:50 (third guide) starting at position 99, 369 and 453 of SEQ ID NO:1. The predicted Cas9 cleavage sites directed by these guide RNAs were designed to overlap with the nucleic acid recognition site of the restriction enzymes: Hinfl, BseLI and BtsI for the first, second and thirdgRNA, respectively (see Fig. 9). Transformation was performed using a DNA plasmid such as a plant codon optimized Streptococcuspyogenes Cas9 (pcoSpCas9) plasmid presented in Fig. 8. The plasmid contained the plant codon optimized SpCas9 and the above mentioned at least one sgRNA.

About two months post transformation, leaves from mature plants were sampled, and their DNA was extracted and digested with the suitable enzymes. Digested genomic DNA was used as a template for PCR using a primer pair flanking the 5' and 3' ends of thefirst exon of CsMLO1. The forward primer (fwd) (5-GAGTGGAACTAGAAGAAATGC-3) comprises a nucleotide sequence as set forth in SEQ ID NO:871, and the reverse primer (rev) (5-CCCTCCAAACACAACAGTGA 3) comprises a nucleotide sequence as set forth in SEQ ID NO:872 (see Fig. 9 and Fig. 10). As shown in Fig. 10, the aforementioned primer pair (marked with arrows) generates a 778 bp amplicon comprising the entire exon 1 of CsMLO1, having a nucleotide sequence as set forth in SEQ ID NO:873 (nucleotide positions 4-782 of SEQ ID NO:1). In Fig. 10 the three gRNA sequences used to target exon 1 of CsMLO1 genomic sequence are underlined. The translation initiation codon ATG (encoding Methionine amino acid) is marked with a square. Fig. 11 presents the amino acid sequence of CsMLO1 first exon as set forth in SEQ ID NO:874.

Reference is now made to Fig. 12 photographically presenting detection of CsMLO1 PCR products showing length variation (i.e. truncated fragments) as a result of Cas9- mediated genome editing. DNA from plants two months post transformation was used as a template for the PCR using primers having nucleic acid sequence as set forth in SEQ ID NO:871 and SEQ ID NO:872. DNA fragments shorter than the expected WT 780 bp amplicon were obtained by the PCR reaction and subcloned into a sequencing plasmid and sequenced. The sequencing results are described below.

It can be seen in Fig. 12 that WT or non-edited PCR products result in a 780 bp band, while DNA extracted from edited plants exhibit a shorter band than the expected 780 bp WT exon 1 length, i.e. samples 1 and 2 show a 450 bp fragment and samples 3 and 4 show a 350 bp fragment.

Fig. 13 schematically presents sequences of WT and genome edited CsMLO1 DNA fragments obtained for the first time by the present invention. In this figure, sgRNA sequences are underlined. sgRNA having nucleotide sequence as set forth in SEQ ID NO:17 (first guide) with Hinfl restriction site appears on the left hand of exon 1, and sgRNA having nucleotide sequence as set forth in SEQ ID NO:50 (third guide) with BtsI restriction site appears on the right hand of exon 1 fragments. PAM sequences (NGG) are in marked italics and bold and are circled. ATG codon position is marked with a square.

The sequencing results show that three CsMLO1 exon 1 genome edited fragments were achieved by the present invention.

Reference is now made to Table 5 summarizing sequences relating to mutated (genome edited) exon 1 fragments of CsMLO1 achieved by the current invention.

Table 5: Sequences of mutated CsMLO1 exon 1

Sequencetype Exon 1 of WT 65-L4 (A447) 65-L5 (A373) 85-4 (A456) CsMLO1 fragment of fragment of fragment of CsMLO1 CsMLO1 CsMLO1

Genomic SEQ ID NO:873 SEQ ID NO:875 SEQ ID NO:877 SEQ ID NO:880 sequence (nucleic acid 4- (deletion of (deletion of (deletion of (Position in SEQ 782 in SEQ ID nucleic acid 109- nucleic acid 128- nucleic acid 96 ID NO:1) NO:1) (Fig. 10) 556 in SEQ ID 501 in SEQ ID 552 in SEQ ID NO:1) (Fig. 13) NO:1) (Fig. 13) NO:1) (Fig. 13)

Deleted nucleic SEQ ID NO:876 SEQ ID NO:879 SEQ ID NO:881 acid sequence

Amino acid SEQ ID NO:874 SEQ ID NO:887 SEQ ID NO:878 No amino- acid sequence (Fig. 11) MS MSGGGEGE sequenceis produced

gRNA sequence SEQ ID NO:17, targeted to Exon SEQ ID NO:43 1 of CsMLO1 and SEQ ID NO:50 (Table 1)

The resulted mutated CsMLO1 fragments include the following:

(1) Fragment 1: CsMLO1 fragment marked as 65-L4 A447 comprises a nucleotide sequence as set forth in SEQ ID NO:875 (about 330 bp). This fragment contains a deletion of 447 bp (position 109-556 of SEQ ID NO:1) having a nucleotide sequence as set forth in SEQ ID NO:876. It should be noted that this fragment encodes a two amino acid peptide (SEQ ID NO:887, as shown in Table 5). The short CsMLO1 exon 1 peptide generated by the targeted genome editing is expected to result is a non-functional, silenced CsMLO1 gene or allele.

(2) Fragment 2: CsMLO1 fragment marked as 65-L5 A373 comprises a nucleotide sequence as set forth in SEQ ID NO:877 (about 405 bp). This fragment contains a deletion of 373 bp (position 128-501 of SEQ ID NO:1) having a nucleotide sequence as set forth in SEQ ID NO:879. It should be noted that this fragment encodes a short peptide of eight amino acids (SEQ ID NO:878, as shown in Table 5). Such a short exon 1 fragment is expected to result in a non-functional CsMLO1 allele.

(3) Fragment 3: CsMLO1 fragment marked as 85-4 A456 comprises a nucleotide sequence as set forth in SEQ ID NO:880 (about 320 bp). This fragment contains a deletion of 456 bp (position 96-552 of SEQ ID NO:1) having a nucleotide sequence as set forth in SEQ ID NO:881. It is emphasized that fragment 3 was edited such that it lacks the ATG translation start codon, therefore no translated protein is generated. The resulted truncated CsMLO1 gene/protein is expected to be non-functional.

The genome-edited CsMLO1 truncated fragments of the present invention are characterized by deletion of significant parts of the first exon sequence of CsMLO1 gene. Thus these genome edited fragments produce truncated CsMLO1 proteins. The truncated proteins lack significant part of the Open Reading Frame (ORF), e.g. absent of the translation start codon or significant part of exon 1 protein encoding sequence, and therefore would be non-functional.

EXAMPLE 4

Production of mutated Csmlol gene by genome editing events

This example presents the production of new genome editing events within CsMLO1 gene. A mutated Csmlol allele has been generated encompassing at least one of the following genome editing events within CsMLO1 gene:

1. indel_d14 - 14pb deletion (bp389-402 of SEQ IDNO:1) having SEQ IDNO:883 2. il- lbp insertion ofA(bp 482-483 of SEQ IDNO:1)

As compared to the WT CsMLO1_378-500 fragment of SEQ ID NO:1 having a nucleic acid sequence as set forth in SEQ ID NO:882, the mutated Csmlol allele may comprise one or more of the following mutated DNA fragments:

-Csmlo1_d14i1 encompassing the above identified deletion and insertion events, comprising a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886.

-Csmlo1_d14 encompassing the above identified deletion event, comprising a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884.

-Csmlol-il encompassing the above identified insertion event, comprising a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885.

The sequence of the mutated DNA fragments Csmlol_dl4i, Csmlo1_d14, Csmlol_il, as well as the presence of a deletion indel_d14 and/or insertion il provided by the present invention, is useful to identify and generate Cannabis plants with mutated alleles of MLO1 gene, desirable for the production of Cannabis plants with PM resistance.

Reference is now made to Fig. 14, schematically presenting sequence comparison (homology) between WT CsMLO1_378-500 fragment of SE ID NO:1, having a nucleic acid sequence as set forth in SEQ ID NO:882, and genome edited Csmlo1_d14i1 fragment, having a nucleic acid sequence as set forth in SEQ ID NO:886. In this figure, the deleted nucleic acids within Csmlo1_d14i1 fragment are marked with dashed line, and the inserted nucleotide (A) is underlined and marked in bold. The gRNA designed to target the deletion region (having a sequence as set forth in SEQ ID NO:43) comprises BslI restriction site and is marked with a square having a continuous line. The gRNA designed to target the insertion region (having a nucleotide sequence complementary to the nucleotide sequence as set forth in SEQ ID NO:50) comprises BtsI restriction site and is marked with a square having a dashed line. PAM sequence regions are marked in bold and italics.

As shown in this figure, specific genome editing events within CsMLO1 gene are generated by the present invention resulting in mutated Csmlol alleles (such as alleles comprising Csmlo_d14, Csmlol_il and Csmlol_dl4i1 fragments). According to one embodiment, a mutated Csmlo allele comprising a deletion of 14 bp (having SEQ ID NO:883) at position corresponding to position 12 of SEQ ID NO: 882 is produced (Csmlo allele containing Csmlold14 fragment). According to a further embodiment, a mutated Csmlo allele comprising a nucleic acid insertion of A at position corresponding to position 104-105 of SEQ ID NO: 882 is produced (Csmlo allele containing Csmloli1 fragment). According to yet another embodiment, a mutated Csmlo allele comprising a deletion of 14 bp (having SEQ ID NO:883) at position corresponding to position 12 of SEQ ID NO: 882 in combination with a nucleic acid insertion of A at position corresponding to position 104-105 of SEQ ID NO: 882 (Csmlo allele containing Csmlo1_d14i1 fragment) is produced.

The genome editing events herein described introduce mutations that silence or significantly reduce CsMLO1 gene expression or function in the plant.

By silencing genes encoding MLO proteins (e.g. CsMLO1, CsMLO2 and/or CsMLO3) in Cannabis, plants with enhanced resistance to Powdery Mildew disease, can be produced. These PM resistant plants are highly desirable for the medical Cannabis industry since usage of chemical agents to control pathogen diseases is significantly reduced or avoided.

Claims

1. A modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein said modified plant comprises a mutated Cannabis mlol (Csmlol) allele, said mutated allele comprising a genomic modification selected from an indel of 14 bp at position corresponding to position 12 of SEQ ID NO: 882, or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof.

2. The modified Cannabis plant according to claim 1, wherein said indel comprises a sequence as set forth in SEQ ID NO:883 or a fraction thereof.

3. The modified Cannabis plant according to claim 1, wherein said Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele, or a complementary sequence thereof, or any combination thereof.

4. The modified Cannabis plant according to claim 1, wherein said Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele.

5. The modified Cannabis plant according to claim 1, wherein said mutated Csmlol allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele having a nucleic acid sequence as set forth in SEQ ID NO:882 and/or having a nucleic acid sequence as set forth in SEQ ID NO:1 or a functional variant thereof.

6. The modified Cannabis plant according to claim 5, wherein said functional variant has at least 80% sequence identity to the corresponding CsMLO1 nucleotide sequence.

7. The modified Cannabis plant according to claim 1, wherein said mutated allele comprising a deletion of 14 bp at position 389 of SEQ ID NO: 1, or a nucleic acid insertion at position 482-483 of SEQ ID NO: 1, or a combination thereof.

8. The modified Cannabis plant according to claim 1 wherein said mutated Csmlol allele is generated using genome editing.

9. The modified Cannabis plant according to claim 1, wherein said plant has decreased expression levels of Mlo l protein, relative to a Cannabis plant lacking said mutated Csmlol allele.

10. The modified Cannabis plant according to claim 1, wherein said mutated Csmlol allele is generated using mutagenesis, small interfering RNA (siRNA), microRNA (miRNA), artificial miRNA (amiRNA), DNA introgression, endonucleases or any combination thereof.

11. The modified Cannabis plant according to claim 10, wherein said endonuclease is selected from the group consisting of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) gene (CRISPR/Cas), Transcription activator-like effector nuclease (TALEN), Zinc Finger Nuclease (ZFN), meganuclease or any combination thereof.

12. The modified Cannabis plant according to claim 11, wherein said Cas gene is selected from the group consisting of Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, Cas1O, CastlOd, Cas12, Cas13, Cas14, CasX, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpfl, Csbl, Csb2, Csb3, Csx17, Csx14, Csx1O, Csx16, CsaX, Csx3, Cszl, Csxl5, Csfl, Csf2, Csf3, Csf4, and Cu1966, bacteriophages Cas such as Cas(D (Cas phi) and any combination thereof.

13. The modified Cannabis plant according to claim 1, wherein said plant comprises a DNA construct, said DNA construct comprising a promoter operably linked to a nucleotide sequence encoding a plant optimized Cas9 endonuclease, wherein said plant optimized Cas9 endonuclease is capable of binding to and creating a double strand break in a genomic target sequence of said plant genome.

14. The modified Cannabis plant according to claim 13, wherein said DNA construct further comprises gRNA targeted to at least one CsMLO1 allele.

15. The modified Cannabis plant according to claim 14, wherein said gRNA has a nucleic acid sequence corresponding to a sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, or any combination thereof.

16. The modified Cannabis plant according to claim 1, wherein said genome modification is a silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation or any combination thereof.

17. The modified Cannabis plant according to claim 1, wherein said genome modification is an insertion, deletion, indel or substitution.

18. The modified Cannabis plant according to claim 1 wherein said genome modification is an induced mutation in the coding region of said allele, a mutation in the regulatory region of said allele, a mutation in a gene downstream in the MLO pathogen response pathway and/or an epigenetic factor.

19. The modified Cannabis plant according to claim 1, wherein said genome modification is generated via introduction (a) Cas DNA and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 and any combination thereof.

20. The modified Cannabis plant according to any one of claims 14, 15 and 18 wherein said gRNA sequence comprises a 3' Protospacer Adjacent Motif (PAM) selected from the group consisting of NGG (SpCas), NNNNGATT (NmeCas9), NNAGAAW (StCas9), NAAAAC (TdCas9), NNGRRT (SaCas9) and TBN (Cas-phi).

21. The modified Cannabis plant according to claim 1, wherein said PM is selected from the group consisting of Golovinomyces cichoracearum, Golovinomyces ambrosiae and a mixture thereof.

22. The modified Cannabis plant according to claim 1 wherein said Cannabis plant is selected from the group of species that includes, but is not limited to, Cannabissativa (C. sativa), C. indica, C. ruderalisand any hybrid or cultivated variety of the genus Cannabis.

23. The modified Cannabis plant according to claim 1 wherein said Cannabis plant does not comprise a transgene.

24. A modified Cannabis plant, progeny plant, plant part or plant cell according to claim 1.

25. A plant part, plant cell or plant seed of a modified plant according to claim 1.

26. A tissue culture of regenerable cells, protoplasts or callus obtained from the modified Cannabis plant according to claim 1.

27. The modified Cannabis plant according to claim 1 wherein said plant genotype is obtainable by deposit under accession number with NCIMB Aberdeen AB21 9YA, Scotland, UK.

28. A modified Cannabis plant exhibiting enhanced resistance to powdery mildew (PM), wherein said modified plant comprises a targeted genome modification conferring reduced expression of a Cannabis MLO1 (CsMLO1) gene as compared to a Cannabis plant lacking said targeted genome modification, said targeted genome modification generates a mutated Cannabis mlol (Csmlol) allele comprising a deletion of a nucleic acid sequence as set forth in SEQ ID NO:883 or a fraction thereof as compared to the wild type CsMLO1 allele comprising a sequence as set forth in SEQ ID NO:1, or a nucleic acid insertion at position 482-483 of SEQ ID NO:1, or a combination thereof.

29. The modified Cannabis plant according to claim 28, wherein said mutated allele comprising a deletion of 14 bp at position 389 of SEQ ID NO: 1, or a nucleic acid insertion at position 482-483 of SEQ ID NO: 1, or a combination thereof.

30. A method for producing a modified Cannabis plant according to any one of claims 1-24 and 27-29, said method comprises introducing using targeted genome modification, at least one genomic modification conferring reduced expression of at least one Cannabis MLO1 (CsMLO1) allele as compared to a Cannabis plant lacking said targeted genome modification, said genomic modification generates a mutated Cannabis mlol (Csmlol) allele comprising an indel of 14 bp at a position corresponding to position 12 of SEQ ID NO: 882 or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof.

31. The method according to claim 30, comprises steps of introducing a loss of function mutation into said CsMLO1 allele using targeted genome modification.

32. The method according to claim 30, wherein said indel comprises a sequence as set forth in SEQ ID NO:883 or a fraction thereof.

33. The method according to claim 30, wherein said Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele, or a complementary sequence thereof, or any combination thereof.

34. The method according to claim 30, wherein said Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele.

35. The method according to claim 30, wherein said mutated Csmlol allele confers an enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 allele having anucleic acid sequence as set forth in SEQ ID NO:882 and/or having a nucleic acid sequence as set forth in SEQ ID NO:1 or a functional variant thereof.

36. The method according to claim 35, wherein said functional variant has at least 80% sequence identity to the corresponding CsMLO1 nucleotide sequence.

37. The method according to claim 30, wherein said mutated allele comprising a deletion of 14 bp at position 389 of SEQ ID NO: 1, or a nucleic acid insertion at position 482-483 of SEQ ID NO: 1, or a combination thereof.

38. The method according to claim 30, wherein said modified plant has decreased levels of at least one Mlo protein as compared to wild type Cannabis plant.

39. The method according to claim 30, wherein said genome modification is introduced using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR associated (Cas) gene (CRISPR/Cas), Transcription activator-like effector nuclease (TALEN), Zinc Finger Nuclease (ZFN), meganuclease or any combination thereof.

40. The method according to claim 39, wherein said Cas gene is selected from the group consisting of Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, Cas1, CastlOd, Casl2, Cas13, Casl4, CasX, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csnl, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpfl, Csbl, Csb2, Csb3, Csxl7, Csxl4, Csxl0, Csxl6, CsaX, Csx3, Cszl, Csxl5, Csfl, Csf2, Csf3, Csf4, and Cu1966, bacteriophages Cas such as Cas(D (Cas-phi) and any combination thereof.

41. The method according to claim 30, comprising steps of introducing an expression vector comprising a promoter operably linked to a nucleotide sequence encoding a plant optimized Cas9 endonuclease and gRNA targeted to at least one CsMLO1 allele.

42. The method according to claim 41 wherein said gRNA nucleotide sequence targeting said CsMLO1 allele is selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof.

43. The method according to claim 30 comprising steps of introducing and co-expressing in a Cannabis plant Cas9 and gRNA targeted to CsMLO1 gene and screening for induced targeted mutations conferring reduced expression of said CsMLO1 gene.

44. The method according to claim 30 wherein said genomic modification is in the coding region of said allele, a mutation in the regulatory region of said allele, a mutation in a gene downstream in the MLO pathogen response pathway or an epigenetic factor.

45. The method according to claim 30, wherein said genomic modification is selected from the group consisting of a silencing mutation, a knockdown mutation, a knockout mutation, a loss of function mutation and any combination thereof.

46. The method according to claim 30, wherein said genomic modification is an insertion, deletion, indel or substitution mutation.

47. The method according to claim 30, further comprising steps of selecting a plant resistant to powdery mildew from plants comprising mutated Csmlo Iallele.

48. The method according to claim 47, wherein said selected plant is characterized by enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a CsMLO1 nucleic acid comprising a nucleic acid sequence as set forth in SEQ ID NO:882.

49. The method according to claim 30, wherein said genetic modification in said CsMLO1 is generated in planta via introduction of a construct comprising (a) Cas DNA and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, and any combination thereof, or (b) a ribonucleoprotein (RNP) complex comprising Cas protein and gRNA sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, and any combination thereof.

50. The method according to any one of claims 41, 42, 43 and 49, wherein said gRNA nucleotide sequence comprises a 3' Protospacer Adjacent Motif (PAM) selected from the group consisting of NGG (SpCas), NNNNGATT (NmeCas9), NNAGAAW (StCas9), NAAAAC (TdCas9), NNGRRT (SaCas9) and TBN (Cas-phi).

51. The method according to claim 30, further comprising steps of regenerating a plant carrying said genomic modification.

52. The method according to claim 51 further comprising steps of screening said regenerated plants for a plant resistant to powdery mildew.

53. A method for conferring powdery mildew resistance to a Cannabis plant comprising producing a plant according to the method of claim 30.

54. A plant, plant part, plant cell, tissue culture or a seed obtained or obtainable by the method of claim 30.

55. The method according to claim 30 wherein said powdery mildew is selected from the group of species consisting of Golovinomyces cichoracearum, Golovinomyces ambrosiae and a mixture thereof.

56. The method according to claim 30 wherein said Cannabis plant is selected from the group of species that includes, but is not limited to, Cannabis sativa (C. sativa), C. indica, C. ruderalisand any hybrid or cultivated variety of the genus Cannabis.

57. A method of determining the presence of a mutant Csmlol allele in a Cannabis plant comprising assaying said Cannabis plant for at least one of the presence of an indel comprising a nucleic acid sequence as set forth in SEQ ID NO:883, an insertion at position 104-105 of SEQ ID NO: 882, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele, a complementary sequence thereof, or any combination thereof.

58. A method for identifying a Cannabis plant with resistance to powdery mildew, said method comprises steps of:

a. screening the genome of said Cannabis plant for a mutated Csmlol allele, said mutated allele comprises a genomic modification selected from an indel of 14 bp at a position corresponding to position 12 of SEQ ID NO: 882 or a fraction thereof, or a nucleic acid insertion at position corresponding to position 104-105 of SEQ ID NO: 882, or a combination thereof; b. optionally, regenerating plants carrying said genetic modification; and c. optionally, screening said regenerated plants for a plant resistant to powdery mildew.

59. The method according to claim 58, wherein said genomic modification is a loss of function mutation.

60. The method according to claim 58, wherein said indel comprises a sequence as set forth in SEQ ID NO:883 or a fraction and/or a complementary sequence thereof.

61. The method according to claim 58, wherein said Csmlol mutant allele comprises a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:884, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:885, or a nucleic acid sequence corresponding to the sequence as set forth in SEQ ID NO:886, or a homologue having at least 80% sequence identity to the nucleic acid sequence of said mutated Csmlol allele, or a complementary sequence thereof, or any combination thereof.

62. The method according to claim 58, wherein said method comprises steps of screening said Cannabis plant for the presence of a deletion in CsMLO1 gene comprising a nucleic acid sequence as set forth in SEQ ID NO:1, said deletion comprising a nucleotide sequence as set forth in SEQ ID NO:883.

63. The method according to claim 58, wherein said modified Cannabis plant comprising a mutant Csmlol nucleic acid conferring enhanced resistance to powdery mildew as compared to a Cannabis plant comprising a wild type CsMLO1 nucleic acid.

64. A method for down regulation of Cannabis MLO1 (CsMLO1) gene, which comprises utilizing the nucleotide sequence as set forth in at least one of SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence thereof, and a combination thereof, for introducing a loss of function mutation into said CsMLO1 gene using targeted genome modification.

65. An isolated amino acid sequence having at least 80% sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:882-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof.

66. Use of a nucleotide sequence as set forth in SEQ ID NO: 883-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 for generating, identifying and/or screening for a Cannabis plant comprising within its genome mutant Csmlo allele conferring resistance to PM.

67. The use according to claim 66, wherein the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:883, SEQ ID NO:882 indicates that the Cannabis plant comprises a wild type CsMLO1 allele, and the presence of at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:884, SEQ ID NO:885 and SEQ ID NO:886 indicates that the Cannabis plant comprises a mutant Csmoll allele.

68. Use of a nucleotide sequence as set forth in at least one of SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof for targeted genome modification of Cannabis MLO1 (CsMLO1) gene.

69. A detection kit for determining the presence or absence of a mutant Csmlol allele in a Cannabis plant, comprising a nucleic acid fragment comprising a sequence selected from SEQ ID NO:882-886, SEQ ID NO:17, SEQ ID NO:43 and SEQ ID NO:50 or a complementary sequence or any combination thereof.

70. The detection kit according to claim 69, wherein said kit is useful for identifying a Cannabis plant with enhanced resistance to powdery mildew.